Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2024

28-02-2024 | Liver Transplantation | Guidelines

Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation

Authors: Dong-Sik Kim, Young-In Yoon, Beom Kyung Kim, Ashok Choudhury, Anand Kulkarni, Jun Yong Park, Jongman Kim, Dong Hyun Sinn, Dong Jin Joo, YoungRok Choi, Jeong-Hoon Lee, Ho Joong Choi, Ki Tae Yoon, Sun Young Yim, Cheon-Soo Park, Deok-Gie Kim, Hae Won Lee, Won-Mook Choi, Young Eun Chon, Woo-Hyoung Kang, Jinsoo Rhu, Jae Geun Lee, Yuri Cho, Pil Soo Sung, Han Ah Lee, Ji Hoon Kim, Si Hyun Bae, Jin Mo Yang, Kyung-Suk Suh, Mamun Al Mahtab, Soek Siam Tan, Zaigham Abbas, Ananta Shresta, Shahinul Alam, Anil Arora, Ashish Kumar, Pravin Rathi, Ruveena Bhavani, Charles Panackel, Kuei Chuan Lee, Jun Li, Ming-Lung Yu, Jacob George, Tawesak Tanwandee, Sen-Yung Hsieh, Chee Chien Yong, Mohamed Rela, H. C. Lin, Masao Omata, Shiv Kumar Sarin, for Asian Pacific Association for Study of Liver (APASL)

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Liver transplantation is a highly complex and challenging field of clinical practice. Although it was originally developed in western countries, it has been further advanced in Asian countries through the use of living donor liver transplantation. This method of transplantation is the only available option in many countries in the Asia-Pacific region due to the lack of deceased organ donation. As a result of this clinical situation, there is a growing need for guidelines that are specific to the Asia-Pacific region. These guidelines provide comprehensive recommendations for evidence-based management throughout the entire process of liver transplantation, covering both deceased and living donor liver transplantation. In addition, the development of these guidelines has been a collaborative effort between medical professionals from various countries in the region. This has allowed for the inclusion of diverse perspectives and experiences, leading to a more comprehensive and effective set of guidelines.
Appendix
Available only for authorised users
Literature
1.
O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764–1776PubMedCrossRef
2.
Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013;10:434–440PubMedCrossRef
3.
Durand F. How to improve long-term outcome after liver transplantation? Liver Int. 2018;38(Suppl 1):134–138PubMedCrossRef
4.
5.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926.
6.
Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, Williams JW, Jr., Kunz R, Craig J, Montori VM, Bossuyt P, Guyatt GH, GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–1110.
7.
Polson J, Lee WM, American Association for the Study of Liver D. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.
8.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66:1047–1081CrossRef
9.
10.
Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332–339PubMedCrossRef
11.
12.
Shen T, Liu Y, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;156:2230-2241.e11PubMedCrossRef
13.
Kumar R, Shalimar, Bhatia V, Khanal S, Sreenivas V, Gupta SD, Panda SK, Acharya SK. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–1674.
14.
Lim YS. Acute liver failure in Korea: etiology, prognosis and treatment. Korean J Hepatol. 2010;16:5–18PubMedCrossRef
15.
Oketani M, Ido A, Nakayama N, Takikawa Y, Naiki T, Yamagishi Y, Ichida T, Mochida S, Onishi S, Tsubouchi H, Intractable Hepato-Biliary Diseases Study Group of Japan. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res. 2013;43:97–105.
16.
Ho CM, Lee CH, Wang JY, Lee PH, Lai HS, Hu RH. Nationwide longitudinal analysis of acute liver failure in taiwan. Medicine (Baltimore). 2014;93:e35PubMedCrossRef
17.
Jindal A, Sarin SK. Epidemiology of liver failure in Asia-Pacific region. Liver Int. 2022;42:2093–2109PubMedCrossRef
18.
Seow HF, Mahomed NM, Mak JW, Riddell MA, Li F, Anderson DA. Seroprevalence of antibodies to hepatitis E virus in the normal blood donor population and two aboriginal communities in Malaysia. J Med Virol. 1999;59:164–168PubMedCrossRef
19.
Bhatia V, Singhal A, Panda SK, Acharya SK. A 20-year single-center experience with acute liver failure during pregnancy: is the prognosis really worse? Hepatology. 2008;48:1577–1585PubMedCrossRef
20.
Javed N, Ullah SH, Hussain N, Sheikh MA, Khan A, Ghafoor F, et al. Hepatitis E virus seroprevalence in pregnant women in Pakistan: maternal and fetal outcomes. East Mediterr Health J. 2017;23:559–563PubMedCrossRef
21.
Gupta N, Sarangi AN, Dadhich S, Dixit VK, Chetri K, Goel A, et al. Acute hepatitis E in India appears to be caused exclusively by genotype 1 hepatitis E virus. Indian J Gastroenterol. 2018;37:44–49PubMedCrossRef
22.
Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523–532PubMedPubMedCentralCrossRef
23.
Hercun J, Koh C, Heller T. Hepatitis delta: prevalence, natural history, and treatment options. Gastroenterol Clin North Am. 2020;49:239–252PubMedCrossRef
24.
Nakao M, Nakayama N, Uchida Y, Tomiya T, Ido A, Sakaida I, et al. Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol. 2018;53:752–769PubMedCrossRef
25.
Noguchi F, Chu PS, Yoshida A, Taniki N, Morikawa R, Hasegawa Y, et al. Early dynamics of MELD scores predict corticosteroid responsiveness to severe acute-onset autoimmune hepatitis. Clin Gastroenterol Hepatol. 2022;20:2641-2643.e3PubMedCrossRef
26.
Hiramatsu A, Takahashi S, Aikata H, Azakami T, Katamura Y, Kawaoka T, et al. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol. 2008;23:1216–1222PubMedCrossRef
27.
Arai S, Kogiso T, Ogasawara Y, Sagawa T, Taniai M, Tokushige K. Long-term outcome of Wilson’s disease complicated by liver disease. JGH Open. 2021;5:793–800PubMedPubMedCentralCrossRef
28.
O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–445PubMedCrossRef
29.
Hadem J, Stiefel P, Bahr MJ, Tillmann HL, Rifai K, Klempnauer J, et al. Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. Clin Gastroenterol Hepatol. 2008;6:339–345PubMedCrossRef
30.
Sugawara K, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. J Gastroenterol. 2012;47:849–861PubMedPubMedCentralCrossRef
31.
32.
33.
Barshes NR, Lee TC, Balkrishnan R, Karpen SJ, Carter BA, Goss JA. Risk stratification of adult patients undergoing orthotopic liver transplantation for fulminant hepatic failure. Transplantation. 2006;81:195–201PubMedCrossRef
34.
Pan ET, Yoeli D, Galvan NTN, Kueht ML, Cotton RT, O’Mahony CA, et al. Cold ischemia time is an important risk factor for post-liver transplant prolonged length of stay. Liver Transpl. 2018;24:762–768PubMedCrossRef
35.
Huang Y, MacQuillan G, Adams LA, Garas G, Collins M, Nwaba A, et al. Effect of airplane transport of donor livers on post-liver transplantation survival. World J Gastroenterol. 2016;22:9154–9161PubMedPubMedCentralCrossRef
36.
37.
Urrunaga NH, Rachakonda VP, Magder LS, Mindikoglu AL. Outcomes of living versus deceased donor liver transplantation for acute liver failure in the United States. Transpl Proc. 2014;46:219–224CrossRef
38.
Jin YJ, Lim YS, Han S, Lee HC, Hwang S, Lee SG. Predicting survival after living and deceased donor liver transplantation in adult patients with acute liver failure. J Gastroenterol. 2012;47:1115–1124PubMedCrossRef
39.
Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, Umeshita K, et al. Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. Liver Transpl. 2012;18:1069–1077PubMedCrossRef
40.
Pamecha V, Vagadiya A, Sinha PK, Sandhyav R, Parthasarathy K, Sasturkar S, et al. Living donor liver transplantation for acute liver failure: donor safety and recipient outcome. Liver Transpl. 2019;25:1408–1421PubMedCrossRef
41.
Mehrotra S, Mehta N, Rao PS, Lalwani S, Mangla V, Nundy S. Live donor liver transplantation for acute liver failure: a single center experience. Indian J Gastroenterol. 2018;37:25–30PubMedCrossRef
42.
Goldaracena N, Spetzler VN, Marquez M, Selzner N, Cattral MS, Greig PD, et al. Live donor liver transplantation: a valid alternative for critically ill patients suffering from acute liver failure. Am J Transpl. 2015;15:1591–1597CrossRef
43.
Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, Saigal S, Saraf N, Soin AS, Devarbhavi H, Kim DJ, Dhiman RK, Duseja A, Taneja S, Eapen CE, Goel A, Ning Q, Chen T, Ma K, Duan Z, Yu C, Treeprasertsuk S, Hamid SS, Butt AS, Jafri W, Shukla A, Saraswat V, Tan SS, Sood A, Midha V, Goyal O, Ghazinyan H, Arora A, Hu J, Sahu M, Rao PN, Lee GH, Lim SG, Lesmana LA, Lesmana CR, Shah S, Prasad VGM, Payawal DA, Abbas Z, Dokmeci AK, Sollano JD, Carpio G, Shresta A, Lau GK, Fazal Karim M, Shiha G, Gani R, Kalista KF, Yuen MF, Alam S, Khanna R, Sood V, Lal BB, Pamecha V, Jindal A, Rajan V, Arora V, Yokosuka O, Niriella MA, Li H, Qi X, Tanaka A, Mochida S, Chaudhuri DR, Gane E, Win KM, Chen WT, Rela M, Kapoor D, Rastogi A, Kale P, Rastogi A, Sharma CB, Bajpai M, Singh V, Premkumar M, Maharashi S, Olithselvan A, Philips CA, Srivastava A, Yachha SK, Wani ZA, Thapa BR, Saraya A, Shalimar, Kumar A, Wadhawan M, Gupta S, Madan K, Sakhuja P, Vij V, Sharma BC, Garg H, Garg V, Kalal C, Anand L, Vyas T, Mathur RP, Kumar G, Jain P, Pasupuleti SSR, Chawla YK, Chowdhury A, Alam S, Song DS, Yang JM, Yoon EL, APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL): an update. Hepatol Int. 2019;13:353–390.
44.
Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gines P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Munoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V, CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61:1038–1047.
45.
Bajaj JS, O'Leary JG, Reddy KR, Wong F, Biggins SW, Patton H, Fallon MB, Garcia-Tsao G, Maliakkal B, Malik R, Subramanian RM, Thacker LR, Kamath PS, North American Consortium For The Study Of End-Stage Liver Disease (NACSELD). Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures. Hepatology. 2014;60:250–256.
46.
47.
Kim TY, Song DS, Kim HY, Sinn DH, Yoon EL, Kim CW, Jung YK, Suk KT, Lee SS, Lee CH, Kim TH, Kim JH, Choe WH, Yim HJ, Kim SE, Baik SK, Lee BS, Jang JY, Suh J, 3rd, Kim HS, Nam SW, Kwon HC, Kim YS, Kim SG, Chae HB, Yang JM, Sohn JH, Lee HJ, Park SH, Han BH, Choi EH, Kim CH, Kim DJ, Korean Acute-on-Chronic Liver Failure Study Group. Characteristics and discrepancies in acute-on-chronic liver failure: need for a unified definition. PLoS ONE. 2016;11:e0146745.
48.
Bajaj JS, O’Leary JG, Lai JC, Wong F, Long MD, Wong RJ, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022;117:225–252PubMedCrossRef
49.
Hong YS, Sinn DH, Gwak GY, Cho J, Kang D, Paik YH, et al. Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World J Gastroenterol. 2016;22:3785–3792PubMedPubMedCentralCrossRef
50.
Yoon EL, Kim TY, Lee CH, Kim TH, Cho HC, Lee SS, Kim SE, Kim HY, Kim CW, Song DS, Yang JM, Sinn DH, Jung YK, Yim HJ, Kim HS, Sohn JH, Kim JH, Choe WH, Lee BS, Kim MY, Jeong SW, Choi E, Kim DJ, Korean Acute-on-Chronic Liver Failure (KACLiF) Study Group. Long-term prognosis of acute-on-chronic liver failure survivors. J Clin Gastroenterol. 2019;53:134–141.
51.
Mahmud N, Sundaram V, Kaplan DE, Taddei TH, Goldberg DS. Grade 1 acute on chronic liver failure is a predictor for subsequent grade 3 failure. Hepatology. 2020;72:230–239PubMedCrossRef
52.
Sundaram V, Shah P, Wong RJ, Karvellas CJ, Fortune BE, Mahmud N, et al. Patients with acute on chronic liver failure grade 3 have greater 14-day waitlist mortality than status-1a patients. Hepatology. 2019;70:334–345PubMedCrossRef
53.
Larsen FS. Artificial liver support in acute and acute-on-chronic liver failure. Curr Opin Crit Care. 2019;25:187–191PubMedCrossRef
54.
Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, et al. Liver transplantation in the most severely ill cirrhotic patients: a multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–715PubMedCrossRef
55.
Georgescu A, Onorato E, Nicolae S, Balnescu S. Aortic coarctation treated by pta and stenting: a case presentation and literature review. Maedica (Bucur). 2015;10:342–347PubMed
56.
Thuluvath PJ, Thuluvath AJ, Hanish S, Savva Y. Liver transplantation in patients with multiple organ failures: Feasibility and outcomes. J Hepatol. 2018;69:1047–1056PubMedCrossRef
57.
Kim JE, Sinn DH, Choi GS, Kim JM, Joh JW, Kang W, et al. Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. Dig Liver Dis. 2021;53:1004–1010PubMedCrossRef
58.
Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, Trebicka J, Elkrief L, Hopf C, Solis-Munoz P, Saliba F, Zeuzem S, Albillos A, Benten D, Montero-Alvarez JL, Chivas MT, Concepcion M, Cordoba J, McCormick A, Stauber R, Vogel W, de Gottardi A, Welzel TM, Domenicali M, Risso A, Wendon J, Deulofeu C, Angeli P, Durand F, Pavesi M, Gerbes A, Jalan R, Moreau R, Gines P, Bernardi M, Arroyo V, Consortium CSIotE-C. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62:243–252.
59.
Linecker M, Krones T, Berg T, Niemann CU, Steadman RH, Dutkowski P, et al. Potentially inappropriate liver transplantation in the era of the “sickest first” policy—a search for the upper limits. J Hepatol. 2018;68:798–813PubMedCrossRef
60.
Petrowsky H, Rana A, Kaldas FM, Sharma A, Hong JC, Agopian VG, et al. Liver transplantation in highest acuity recipients: identifying factors to avoid futility. Ann Surg. 2014;259:1186–1194PubMedCrossRef
61.
Queck A, Weiler N, Trebicka J. Transplantation in acute-on-chronic liver failure: feasibility and futility. Clin Liver Dis (Hoboken). 2022;19:191–193PubMedCrossRef
62.
Choudhury A, Vijayaraghavan R, Maiwall R, Kumar M, Duan Z, Yu C, Hamid SS, Jafri W, Butt AS, Devarbhavi H, Ning Q, Ma K, Tan SS, Shukla A, Dhiman R, Duseja A, Taneja S, Eapen CE, Goel A, Treeprasertsuk S, Al-Mahtab M, Ghazinyan H, Kim DJ, Sahu MK, Lee GH, Lesmana LA, Lesmana RC, Shah S, Abbas Z, Sollano JD, Rao PN, Kulkarni A, Shiha G, Shrestha A, Dokmeci A, Yuen MF, Payawal DA, Kalista KF, Prasad VGM, Lau GK, Karim F, Jain P, Kumar G, Arora V, Pamecha V, Sinha P, Sarin SK, Party AARCfAAW. 'First week' is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure. Hepatol Int. 2021;15:1376–1388.
63.
Song DS, Kim TY, Kim DJ, Kim HY, Sinn DH, Yoon EL, Kim CW, Jung YK, Suk KT, Lee SS, Lee CH, Kim TH, Choe WH, Yim HJ, Kim SE, Baik SK, Jang JY, Kim HS, Kim SG, Yang JM, Sohn JH, Choi EH, Cho HC, Jeong SW, Kim MY, Korean Acute-on-Chronic Liver Failure (KACLiF) Study Group. Validation of prognostic scores to predict short-term mortality in patients with acute-on-chronic liver failure. J Gastroenterol Hepatol. 2018;33:900–909.
64.
Huebener P, Sterneck MR, Bangert K, Drolz A, Lohse AW, Kluge S, et al. Stabilisation of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival. Aliment Pharmacol Ther. 2018;47:1502–1510PubMedCrossRef
65.
Sundaram V, Kogachi S, Wong RJ, Karvellas CJ, Fortune BE, Mahmud N, et al. Effect of the clinical course of acute-on-chronic liver failure prior to liver transplantation on post-transplant survival. J Hepatol. 2020;72:481–488PubMedCrossRef
66.
Sundaram V, Jalan R, Wu T, Volk ML, Asrani SK, Klein AS, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019;156:1381-1391.e3PubMedCrossRef
67.
Goosmann L, Buchholz A, Bangert K, Fuhrmann V, Kluge S, Lohse AW, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41:574–584PubMedCrossRef
68.
Sundaram V, Lindenmeyer CC, Shetty K, Rahimi RS, Al-Attar A, Flocco G, Fortune BE, Gong C, Challa S, Maddur H, Jou JH, Kriss M, Stein LL, Xiao AH, Vyhmeister RH, Green EW, Campbell B, Piscitello AJ, Cranford W, Levitsky J, Karvellas CJ, Multi-Organ D, Evaluation for Liver Transplantation C. Patients With Acute-on-Chronic Liver Failure Have Greater Healthcare Resource Utilization After Liver Transplantation. Clin Gastroenterol Hepatol. 2023;21:704–712 e703.
69.
Wang YC, Yong CC, Lin CC, Alam H, Naseer F, Lin YH, et al. Excellent outcome in living donor liver transplantation: treating patients with acute-on-chronic liver failure. Liver Transpl. 2021;27:1633–1643PubMedCrossRef
70.
Jalan R, Yurdaydin C, Bajaj JS, Acharya SK, Arroyo V, Lin HC, Gines P, Kim WR, Kamath PS, World Gastroenterology Organization Working Party. Toward an improved definition of acute-on-chronic liver failure. Gastroenterology. 2014;147:4–10.
71.
Moon DB, Lee SG, Kang WH, Song GW, Jung DH, Park GC, et al. Adult living donor liver transplantation for acute-on-chronic liver failure in high-model for end-stage liver disease score patients. Am J Transpl. 2017;17:1833–1842CrossRef
72.
Yadav SK, Saraf N, Choudhary NS, Sah JK, Sah SK, Rastogi A, et al. Living donor liver transplantation for acute-on-chronic liver failure. Liver Transpl. 2019;25:459–468PubMedCrossRef
73.
Cotter TG, Sundaram V. Living donor liver transplantation in acute-on-chronic liver failure: encouraging outcomes but with important caveats. Liver Transpl. 2021;27:1532–1534PubMedCrossRef
74.
Iwaki K, Yagi S, Morita S, Hamaguchi Y, Masano Y, Yamamoto G, et al. Impact of graft quality and fluid overload on postoperative massive ascites after living donor liver transplantation. Transpl Proc. 2019;51:1779–1784CrossRef
75.
Singal AK, Kuo YF, Waleed M, Wong RJ, Sundaram V, Jalan R. High-risk liver transplant recipients with grade 3 acute on chronic liver failure should receive the good quality graft. Liver Int. 2022;42:1629–1637PubMedCrossRef
76.
Mochida S, Nakayama N, Ido A, Inoue K, Genda T, Takikawa Y, et al. Proposed diagnostic criteria for acute-on-chronic liver failure in Japan. Hepatol Res. 2018;48:219–224PubMedCrossRef
77.
Toshima T, Harada N, Itoh S, Morita K, Nagao Y, Kurihara T, et al. Outcomes of living-donor liver transplantation for acute-on-chronic liver failure based on newly proposed criteria in Japan. Clin Transpl. 2022;36:e14739CrossRef
78.
D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int. 2018;12:34–43PubMedCrossRef
79.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–974.
80.
Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: role of predisposing factors and precipitating events. J Hepatol. 2021;75(Suppl 1):S36–S48PubMedCrossRef
81.
Planas R, Montoliu S, Balleste B, Rivera M, Miquel M, Masnou H, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–1394PubMedCrossRef
82.
D’Amico G, Morabito A, D’Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68:563–576PubMedCrossRef
83.
Jalan R, D’Amico G, Trebicka J, Moreau R, Angeli P, Arroyo V. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. J Hepatol. 2021;75(Suppl 1):S14–S26PubMedCrossRef
84.
Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transpl. 2005;5:307–313CrossRef
85.
Somsouk M, Kornfield R, Vittinghoff E, Inadomi JM, Biggins SW. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transpl. 2011;17:129–136PubMedPubMedCentralCrossRef
86.
Wedd J, Bambha KM, Stotts M, Laskey H, Colmenero J, Gralla J, et al. Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation. Liver Transpl. 2014;20:1193–1201PubMedPubMedCentralCrossRef
87.
88.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–460.
89.
Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176–182PubMedCrossRef
90.
Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int. 2020;40(Suppl 1):22–26PubMedCrossRef
91.
Gentile I, Scotto R, Coppola C, Staiano L, Amoruso DC, De Simone T, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). Hepatol Int. 2019;13:66–74PubMedCrossRef
92.
An J, Park DA, Ko MJ, Ahn SB, Yoo JJ, Jun DW, et al. Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis. J Pers Med. 2022;12:1517PubMedPubMedCentralCrossRef
93.
Thomes PG, Rasineni K, Saraswathi V, Kharbanda KK, Clemens DL, Sweeney SA, et al. Natural recovery by the liver and other organs after chronic alcohol use. Alcohol Res. 2021;41:05PubMedPubMedCentralCrossRef
94.
95.
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370PubMedCrossRef
96.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699PubMedCrossRef
97.
Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–22.
98.
Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203–217PubMedCrossRef
99.
Koh JH, Tan DJH, Ong Y, Lim WH, Ng CH, Tay PWL, et al. Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. Hepatobiliary Surg Nutr. 2022;11:78–93PubMedPubMedCentralCrossRef
100.
Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394–1403PubMedCrossRef
101.
Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008;14:935–945PubMedCrossRef
102.
Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P, Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
103.
Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, Tomiyama K, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery. 2013;154:1053–1060PubMedCrossRef
104.
Chen J, Xu X, Wu J, Ling Q, Wang K, Wang W, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS ONE. 2014;9:e93128PubMedPubMedCentralCrossRef
105.
Hu Z, Qian Z, Wu J, Zhou J, Zhang M, Zhou L, et al. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation. Clin Res Hepatol Gastroenterol. 2016;40:315–326PubMedCrossRef
106.
Goldaracena N, Gorgen A, Doyle A, Hansen BE, Tomiyama K, Zhang W, Ghanekar A, Lilly L, Cattral M, Galvin Z, Selzner M, Bhat M, Selzner N, McGilvray I, Greig PD, Grant DR, Sapisochin G. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation. J Hepatol. 2019;70:666–673.
107.
Wong TCL, Ng KKC, Fung JYY, Chan AAC, Cheung TT, Chok KSH, et al. Long-term survival outcome between living donor and deceased donor liver transplant for hepatocellular carcinoma: intention-to-treat and propensity score matching analyses. Ann Surg Oncol. 2019;26:1454–1462PubMedCrossRef
108.
Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, Kim GS, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transpl Proc. 2014;46:726–729CrossRef
109.
Akamatsu N, Sugawara Y, Kokudo N. Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol. 2014;6:626–631PubMedPubMedCentralCrossRef
110.
Lee SD, Lee B, Kim SH, Joo J, Kim SK, Kim YK, et al. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose—positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transpl. 2016;6:411–422CrossRef
111.
Uchiyama H, Itoh S, Yoshizumi T, Ikegami T, Harimoto N, Soejima Y, et al. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient selection by Kyushu University Criteria in 7 years. HPB (Oxford). 2017;19:1082–1090PubMedCrossRef
112.
Lee HW, Suh KS. Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma. Curr Opin Organ Transpl. 2016;21:231–237CrossRef
113.
Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging? Hepatology. 2016;63:1014–1025PubMedCrossRef
114.
Ravaioli M, Odaldi F, Cucchetti A, Trevisani F, Piscaglia F, De Pace V, et al. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria. Sci Rep. 2019;9:3781PubMedPubMedCentralCrossRef
115.
Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver transplantation for hepatocellular carcinoma. Working group report from the ilts transplant oncology consensus conference. Transplantation. 2020;104:1136–1142.
116.
Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–1977PubMedCrossRef
117.
Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681–693PubMedCrossRef
118.
Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transpl. 2008;8:2547–2557CrossRef
119.
Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transpl. 2015;21:1142–1152PubMedCrossRef
120.
Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within milan criteria: a multicenter study. Clin Gastroenterol Hepatol. 2018;16:955–964PubMedCrossRef
121.
Mehta N, Dodge JL, Grab JD, Yao FY. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence of tumor burden, alpha-fetoprotein, and wait time. Hepatology. 2020;71:943–954PubMedCrossRef
122.
Kardashian A, Florman SS, Haydel B, Ruiz RM, Klintmalm GB, Lee DD, Taner CB, Aucejo F, Tevar AD, Humar A, Verna EC, Halazun KJ, Chapman WC, Vachharajani N, Hoteit M, Levine MH, Nguyen MH, Melcher ML, Langnas AN, Carney CA, Mobley C, Ghobrial M, Amundsen B, Markmann JF, Sudan DL, Jones CM, Berumen J, Hemming AW, Hong JC, Kim J, Zimmerman MA, Nydam TL, Rana A, Kueht ML, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Liver transplantation outcomes in a U.S. Multicenter Cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria. Hepatology. 2020;72:2014–2028.
123.
Mehta N, Frenette C, Tabrizian P, Hoteit M, Guy J, Parikh N, et al. Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium. Gastroenterology. 2021;161:1502–1512PubMedCrossRef
124.
Tan DJH, Lim WH, Yong JN, Ng CH, Muthiah MD, Tan EX, Xiao J, Lim SY, Pin Tang AS, Pan XH, Kabir T, Bonney GK, Sundar R, Syn N, Kim BK, Dan YY, Noureddin M, Loomba R, Huang DQ. UNOS Down-staging criteria for liver transplantation of hepatocellular carcinoma: systematic review and meta-analysis of 25 studies. Clin Gastroenterol Hepatol. 2022. https://​doi.​org/​10.​1016/​j.​cgh.​2022.​02.​018. Epub 2022 Feb 16.
125.
Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol. 1997;15:947–954PubMedCrossRef
126.
Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B Jr, McCashland T, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transpl. 2002;2:774–779CrossRef
127.
Rosen CB, Darwish Murad S, Heimbach JK, Nyberg SL, Nagorney DM, Gores GJ. Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary? J Am Coll Surg. 2012;215:31–38 (Discussion 38–40).
128.
Duignan S, Maguire D, Ravichand CS, Geoghegan J, Hoti E, Fennelly D, et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford). 2014;16:91–98PubMedCrossRef
129.
Welling TH, Feng M, Wan S, Hwang SY, Volk ML, Lawrence TS, et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl. 2014;20:81–88PubMedCrossRef
130.
Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294–303PubMedCrossRef
131.
Zilbert N, Sapisochin G. Time to reconsider liver transplantation for intrahepatic cholangiocarcinoma? Lancet Gastroenterol Hepatol. 2018;3:294–295PubMedCrossRef
132.
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143:88-98.e3PubMedCrossRef
133.
Machairas N, Kostakis ID, Tsilimigras DI, Prodromidou A, Moris D. Liver transplantation for hilar cholangiocarcinoma: a systematic review. Transpl Rev (Orlando). 2020;34:100516CrossRef
134.
Rodríguez-Perálvarez M, Gómez-Bravo MA, Sánchez-Antolín G, De la Rosa G, Bilbao I, Colmenero J, Panel SSoLTSC. Expanding Indications of Liver Transplantation in Spain: Consensus Statement and Recommendations by the Spanish Society of Liver Transplantation. Transplantation. 2021;105:602–607.
135.
Coronary artery surgery. Curr Opin Cardiol. 1996;11:B153–166
136.
Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257:800–806PubMedCrossRef
137.
Toso C, Pinto Marques H, Andres A, Castro Sousa F, Adam R, Kalil A, Clavien PA, Furtado E, Barroso E, Bismuth H, Compagnons Hépato-Biliaires Group. Liver transplantation for colorectal liver metastasis: Survival without recurrence can be achieved. Liver Transpl. 2017;23:1073–1076.
138.
Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bjornbeth BA, et al. Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg. 2020;271:212–218PubMedCrossRef
139.
Smedman TM, Line PD, Hagness M, Syversveen T, Grut H, Dueland S. Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open. 2020;4:467–477PubMedPubMedCentralCrossRef
140.
Giannis D, Sideris G, Kakos CD, Katsaros I, Ziogas IA. The role of liver transplantation for colorectal liver metastases: a systematic review and pooled analysis. Transpl Rev (Orlando). 2020;34:100570CrossRef
141.
Hibi T, Rela M, Eason JD, Line PD, Fung J, Sakamoto S, Selzner N, Man K, Ghobrial RM, Sapisochin G. Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation. 2020;104:1131–1135.
142.
Konigsrainer A, Templin S, Capobianco I, Konigsrainer I, Bitzer M, Zender L, et al. Paradigm shift in the management of irresectable colorectal liver metastases: living donor auxiliary partial orthotopic liver transplantation in combination with two-stage hepatectomy (LD-RAPID). Ann Surg. 2019;270:327–332PubMedCrossRef
143.
Gabbiani G, Ryan GB, Majno G. Morphology and function of granulation tissue. Nouv Rev Fr Hematol. 1972;12:702PubMed
144.
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47:460–466PubMedCrossRef
145.
Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
146.
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, Krenning E, Knigge U, Salazar R, Pape UF, Oberg K, Vienna Consensus Conference participants. ENETS Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–185.
147.
Le Treut YP, Gregoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O, Mantion G, Homayounfar K, Bustamante M, Azoulay D, Wolf P, Krawczyk M, Pascher A, Suc B, Chiche L, de Urbina JO, Mejzlik V, Pascual M, Lodge JP, Gruttadauria S, Paye F, Pruvot FR, Thorban S, Foss A, Adam R, For ELITA. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807–815.
148.
Stump R, Haueis S, Kalt N, Tschuor C, Limani P, Raptis DA, et al. Transplantation and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews. JMIR Res Protoc. 2013;2:e58PubMedPubMedCentralCrossRef
149.
Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113:70–84PubMedCrossRef
150.
Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107:2108–2121PubMedCrossRef
151.
Marino IR, Todo S, Tzakis AG, Klintmalm G, Kelleher M, Iwatsuki S, et al. Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation. Cancer. 1988;62:2079–2084PubMedCrossRef
152.
Madariaga JR, Marino IR, Karavias DD, Nalesnik MA, Doyle HR, Iwatsuki S, et al. Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma. Ann Surg Oncol. 1995;2:483–487PubMedPubMedCentralCrossRef
153.
Lerut JP, Orlando G, Sempoux C, Ciccarelli O, Van Beers BE, Danse E, et al. Hepatic haemangioendothelioma in adults: excellent outcome following liver transplantation. Transpl Int. 2004;17:202–207PubMedCrossRef
154.
Lerut JP, Orlando G, Adam R, Schiavo M, Klempnauer J, Mirza D, Boleslawski E, Burroughs A, Selles CF, Jaeck D, Pfitzmann R, Salizzoni M, Soderdahl G, Steininger R, Wettergren A, Mazzaferro V, Le Treut YP, Karam V, European Liver Transplant Registry. The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. Ann Surg. 2007;246:949–957; discussion 957.
155.
Lai Q, Feys E, Karam V, Adam R, Klempnauer J, Oliverius M, Mazzaferro V, Pascher A, Remiszewski P, Isoniemi H, Pirenne J, Foss A, Ericzon BG, Markovic S, Lerut JP, European Liver Intestine Transplant Association (ELITA). Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry. Transplantation. 2017;101:555–564.
156.
Ahearn A. Ethical dilemmas in liver transplant organ allocation: Is it time for a new mathematical model? AMA J Ethics. 2016;18:126–132PubMedCrossRef
157.
Alsager M, Neong SF, Gandhi R, Teriaky A, Tang E, Skaro A, et al. Liver transplantation in adult polycystic liver disease: the Ontario experience. BMC Gastroenterol. 2021;21:115PubMedPubMedCentralCrossRef
158.
Lange UG, Bucher JN, Schoenberg MB, Benzing C, Schmelzle M, Gradistanac T, et al. Orthotopic liver transplantation for giant liver haemangioma: a case report. World J Transpl. 2015;5:354–359CrossRef
159.
Sundar Alagusundaramoorthy S, Vilchez V, Zanni A, Sourianarayanane A, Maynard E, Shah M, et al. Role of transplantation in the treatment of benign solid tumors of the liver: a review of the United Network of Organ Sharing data set. JAMA Surg. 2015;150:337–342PubMedCrossRef
160.
Prodromidou A, Machairas N, Garoufalia Z, Kostakis ID, Tsaparas P, Paspala A, et al. Liver transplantation for giant hepatic hemangioma: a systematic review. Transpl Proc. 2019;51:440–442CrossRef
161.
Ziogas IA, Tasoudis PT, Serifis N, Alexopoulos SP, Montenovo MI, Shingina A. Liver transplantation for hepatic adenoma: a UNOS database analysis and systematic review of the literature. Transpl Direct. 2022;8:e1264CrossRef
162.
Chiche L, David A, Adam R, Oliverius MM, Klempnauer J, Vibert E, et al. Liver transplantation for adenomatosis: European experience. Liver Transpl. 2016;22:516–526PubMedCrossRef
163.
Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg. 1997;3:628–637PubMedCrossRef
164.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871PubMedCrossRef
165.
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470PubMedCrossRef
166.
Brown RS, Rush SH, Rosen HR, Langnas AN, Klintmalm GB, Hanto DW, et al. Liver and intestine transplantation. Am J Transpl. 2004;4(Suppl 9):81–92CrossRef
167.
Massie AB, Chow EK, Wickliffe CE, Luo X, Gentry SE, Mulligan DC, et al. Early changes in liver distribution following implementation of Share 35. Am J Transpl. 2015;15:659–667CrossRef
168.
Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2-year results of “Share 35.” Liver Transpl. 2016;22:399–409PubMedCrossRef
169.
Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336–343PubMedCrossRef
170.
Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–1660PubMedCrossRef
171.
Londono MC, Cardenas A, Guevara M, Quinto L, de Las HD, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283–1290PubMedPubMedCentralCrossRef
172.
Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–1026PubMedPubMedCentralCrossRef
173.
Cullaro G, Sarkar M, Lai JC. Sex-based disparities in delisting for being “too sick” for liver transplantation. Am J Transpl. 2018;18:1214–1219CrossRef
174.
Allen AM, Heimbach JK, Larson JJ, Mara KC, Kim WR, Kamath PS, et al. Reduced access to liver transplantation in women: role of height, MELD exception scores, and renal function underestimation. Transplantation. 2018;102:1710–1716PubMedPubMedCentralCrossRef
175.
Rubin JB, Sinclair M, Rahimi RS, Tapper EB, Lai JC. Women on the liver transplantation waitlist are at increased risk of hospitalization compared to men. World J Gastroenterol. 2019;25:980–988PubMedPubMedCentralCrossRef
176.
Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, Wood NL, Gentry SE, Kwong AJ. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology. 2021;161:1887–1895 e4.
177.
Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl. 2010;16:262–278PubMedCrossRef
178.
Heimbach JK, Hirose R, Stock PG, Schladt DP, Xiong H, Liu J, et al. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States. Hepatology. 2015;61:1643–1650PubMedCrossRef
179.
Hernaez R, Liu Y, Kramer JR, Rana A, El-Serag HB, Kanwal F. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure. J Hepatol. 2020;73:1425–1433PubMedPubMedCentralCrossRef
180.
Sundaram V, Shah P, Mahmud N, Lindenmeyer CC, Klein AS, Wong RJ, Karvellas CJ, S KA, Jalan R. Patients with severe acute-on-chronic liver failure are disadvantaged by model for end-stage liver disease-based organ allocation policy. Aliment Pharmacol Ther. 2020;52:1204–1213.
181.
Weiss E, Saner F, Asrani SK, Biancofiore G, Blasi A, Lerut J, et al. When is a critically ill cirrhotic patient too sick to transplant? development of consensus criteria by a multidisciplinary panel of 35 international experts. Transplantation. 2021;105:561–568PubMedCrossRef
182.
Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790–1800PubMedCrossRef
183.
Lee BP, Mehta N, Platt L, Gurakar A, Rice JP, Lucey MR, et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology. 2018;155:422-430 e421PubMedCrossRef
184.
Im GY, Neuberger J. Debate on selection criteria for liver transplantation for alcoholic hepatitis: tighten or loosen? Liver Transpl. 2020;26:916–921PubMedCrossRef
185.
Lee BP, Vittinghoff E, Hsu C, Han H, Therapondos G, Fix OK, et al. Predicting low risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the sustained alcohol use post-liver transplant score. Hepatology. 2019;69:1477–1487PubMedCrossRef
186.
Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18:1209–1216PubMedCrossRef
187.
van Vugt JLA, Alferink LJM, Buettner S, Gaspersz MP, Bot D, Darwish Murad S, Feshtali S, van Ooijen PMA, Polak WG, Porte RJ, van Hoek B, van den Berg AP, Metselaar HJ, IJzermans JNM. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: a competing risk analysis in a national cohort. J Hepatol. 2018;68:707–714.
188.
Croome KP, Lee DD, Keaveny AP, Taner CB. Noneligible donors as a strategy to decrease the organ shortage. Am J Transpl. 2017;17:1649–1655CrossRef
189.
Aby ES, Lake JR. Basic principles of liver allocation and development over the years. Curr Opin Organ Transplant. 2020;25:99–103PubMedCrossRef
190.
Freeman RB, Jamieson N, Schaubel DE, Porte RJ, Villamil FG. Who should get a liver graft? J Hepatol. 2009;50:664–673PubMedCrossRef
191.
Choi JY, Kim JH, Kim JM, Kim HJ, Ahn HS, Joh JW. Outcomes of living liver donors are worse than those of matched healthy controls. J Hepatol. 2022;76:628–638PubMedCrossRef
192.
O’Dell HW, McMichael BJ, Lee S, Karp JL, VanHorn RL, Karp SJ. Public attitudes toward contemporary issues in liver allocation. Am J Transpl. 2019;19:1212–1217CrossRef
193.
Schiano TD, Rhodes R. The Ethics of living related liver transplantation when deceased donation is not an option. Clin Liver Dis (Hoboken). 2015;6:112–116PubMedCrossRef
194.
Keller EJ, Kwo PY, Helft PR. Ethical considerations surrounding survival benefit-based liver allocation. Liver Transpl. 2014;20:140–146PubMedCrossRef
195.
196.
Aduen JF, Sujay B, Dickson RC, Heckman MG, Hewitt WR, Stapelfeldt WH, et al. Outcomes after liver transplant in patients aged 70 years or older compared with those younger than 60 years. Mayo Clin Proc. 2009;84:973–978PubMedPubMedCentralCrossRef
197.
European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64:433–485CrossRef
198.
McCaughan GW. Trekking new ground: overcoming medical and social impediments for extended criteria liver transplant recipients. Liver Transpl. 2012;18(Suppl 2):S39-46PubMedCrossRef
199.
An J, Shim JH, Kim SO, Lee D, Kim KM, Lim YS, et al. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case–control study. Circulation. 2014;130:1353–1362PubMedCrossRef
200.
Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol. 2006;98:178–181PubMedCrossRef
201.
Skaro AI, Gallon LG, Lyuksemburg V, Jay CL, Zhao L, Ladner DP, et al. The impact of coronary artery disease on outcomes after liver transplantation. J Cardiovasc Med (Hagerstown). 2016;17:875–885PubMedCrossRef
202.
Konerman MA, Fritze D, Weinberg RL, Sonnenday CJ, Sharma P. Incidence of and risk assessment for adverse cardiovascular outcomes after liver transplantation: a systematic review. Transplantation. 2017;101:1645–1657PubMedPubMedCentralCrossRef
203.
Alexander S, Teshome M, Patel H, Chan EY, Doukky R. The diagnostic and prognostic utility of risk factors defined by the AHA/ACCF on the evaluation of cardiac disease in liver transplantation candidates. BMC Cardiovasc Disord. 2019;19:102PubMedPubMedCentralCrossRef
204.
VanWagner LB, Serper M, Kang R, Levitsky J, Hohmann S, Abecassis M, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample. Am J Transpl. 2016;16:2684–2694CrossRef
205.
Patel SS, Nabi E, Guzman L, Abbate A, Bhati C, Stravitz RT, et al. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. Liver Transpl. 2018;24:333–342PubMedCrossRef
206.
Cheng XS, VanWagner LB, Costa SP, Axelrod DA, Bangalore S, Norman SP, Herzog CA, Lentine KL, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Cardiovascular Radiology and Intervention. Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation. Circulation. 2022;146:e299–e324.
207.
Wray C, Scovotti JC, Tobis J, Niemann CU, Planinsic R, Walia A, et al. Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. Am J Transpl. 2013;13:184–191CrossRef
208.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S, ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618–3731.
209.
Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100:520–528PubMedCrossRef
210.
Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol. 1991;17:492–498PubMedCrossRef
211.
Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401–409PubMedCrossRef
212.
Rodríguez-Roisin R, Krowka MJ, Herve P, Fallon MB, ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004;24:861–880.
213.
Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44:1502–1510PubMedCrossRef
214.
Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: mayo clinic experience categorized by treatment subgroups. Am J Transpl. 2008;8:2445–2453CrossRef
215.
Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363:1461–1468PubMedCrossRef
216.
Ashfaq M, Chinnakotla S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transpl. 2007;7:1258–1264CrossRef
217.
Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl. 2007;13:875–885PubMedCrossRef
218.
Hollatz TJ, Musat A, Westphal S, Decker C, D’Alessandro AM, Keevil J, et al. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl. 2012;18:686–695PubMedCrossRef
219.
Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56:810–818PubMedCrossRef
220.
Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011;60:702–709PubMedCrossRef
221.
Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transpl. 2008;8:2243–2251.
222.
Cruz RJ Jr, Dew MA, Myaskovsky L, Goodpaster B, Fox K, Fontes P, et al. Objective radiologic assessment of body composition in patients with end-stage liver disease: going beyond the BMI. Transplantation. 2013;95:617–622PubMedPubMedCentralCrossRef
223.
Dick AA, Spitzer AL, Seifert CF, Deckert A, Carithers RL Jr, Reyes JD, et al. Liver transplantation at the extremes of the body mass index. Liver Transpl. 2009;15:968–977PubMedCrossRef
224.
225.
DiMartini A, Crone C, Dew MA. Alcohol and substance use in liver transplant patients. Clin Liver Dis. 2011;15:727–751PubMedCrossRef
226.
Rosenberger EM, Dew MA, Crone C, DiMartini AF. Psychiatric disorders as risk factors for adverse medical outcomes after solid organ transplantation. Curr Opin Organ Transplant. 2012;17:188–192PubMedPubMedCentralCrossRef
227.
228.
Pungpapong S, Manzarbeitia C, Ortiz J, Reich DJ, Araya V, Rothstein KD, et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl. 2002;8:582–587PubMedCrossRef
229.
Leithead JA, Ferguson JW, Hayes PC. Smoking-related morbidity and mortality following liver transplantation. Liver Transpl. 2008;14:1159–1164PubMedCrossRef
230.
van der Heide F, Dijkstra G, Porte RJ, Kleibeuker JH, Haagsma EB. Smoking behavior in liver transplant recipients. Liver Transpl. 2009;15:648–655PubMedCrossRef
231.
Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009;137:2010–2017PubMedCrossRef
232.
Herrero JI, Pardo F, D’Avola D, Alegre F, Rotellar F, Inarrairaegui M, et al. Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: the effect of smoking withdrawal. Liver Transpl. 2011;17:402–408PubMedCrossRef
233.
Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022–2033PubMedCrossRef
234.
Burton JR, Jr., Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR, Virahep-C Study Group. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol. 2008;49:329–338.
235.
Fagiuoli S, Colli A, Bruno R, Craxi A, Gaeta GB, Grossi P, Mondelli MU, Puoti M, Sagnelli E, Stefani S, Toniutto P, Burra P, 2011 AISF Single Topic Group. Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. J Hepatol. 2014;60:1075–1089.
236.
Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transpl. 2007;7:2797–2801CrossRef
237.
Subramanian AK, Theodoropoulos NM, Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transpl. 2019;33:e13513.
238.
Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transpl. 2019;33:e13563.
239.
Wadei HM, Gonwa TA, Leoni JC, Shah SZ, Aslam N, Speicher LL. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination. Am J Transpl. 2021;21:3496–3499CrossRef
240.
Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74:944–951PubMedPubMedCentralCrossRef
241.
Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662PubMedCrossRef
242.
Ponziani FR, Zocco MA, Senzolo M, Pompili M, Gasbarrini A, Avolio AW. Portal vein thrombosis and liver transplantation: implications for waiting list period, surgical approach, early and late follow-up. Transpl Rev (Orlando). 2014;28:92–101CrossRef
243.
Zanetto A, Rodriguez-Kastro KI, Germani G, Ferrarese A, Cillo U, Burra P, et al. Mortality in liver transplant recipients with portal vein thrombosis—an updated meta-analysis. Transpl Int. 2018;31:1318–1329PubMedCrossRef
244.
Charco R, Fuster J, Fondevila C, Ferrer J, Mans E, Garcia-Valdecasas JC. Portal vein thrombosis in liver transplantation. Transpl Proc. 2005;37:3904–3905CrossRef
245.
Stange B, Glanemann M, Nussler NC, Bechstein WO, Neuhaus P, Settmacher U. Indication, technique, and outcome of portal vein arterialization in orthotopic liver transplantation. Transpl Proc. 2001;33:1414–1415CrossRef
246.
Alexopoulos SP, Thomas E, Berry E, Whang G, Matsuoka L. The portal vein-variceal anastomosis: an important technique for establishing portal vein inflow. Clin Transpl. 2014;28:52–57CrossRef
247.
Lee S, Kim DJ, Kim IG, Jeon JY, Jung JP, Choi GS, et al. Use of pericholedochal plexus for portal flow reconstruction in diffuse portal vein thrombosis: case report. Transpl Proc. 2014;46:977–979CrossRef
248.
Conzen KD, Pomfret EA. Liver transplant in patients with portal vein thrombosis: medical and surgical requirements. Liver Transpl. 2017;23:S59–S63PubMedCrossRef
249.
Yerdel MA, Gunson B, Mirza D, Karayalcin K, Olliff S, Buckels J, et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation. 2000;69:1873–1881PubMedCrossRef
250.
Lendoire J, Raffin G, Cejas N, Duek F, Barros Schelotto P, Trigo P, et al. Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford). 2007;9:352–356PubMedCrossRef
251.
Angelico M, Nardi A, Romagnoli R, Marianelli T, Corradini SG, Tandoi F, Gavrila C, Salizzoni M, Pinna AD, Cillo U, Gridelli B, De Carlis LG, Colledan M, Gerunda GE, Costa AN, Strazzabosco M, Liver Match Study Investigators. A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the liver match study. Dig Liver Dis. 2014;46:340–347.
252.
Chen H, Turon F, Hernandez-Gea V, Fuster J, Garcia-Criado A, Barrufet M, et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transpl. 2016;22:352–365PubMedCrossRef
253.
Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57:203–212PubMedCrossRef
254.
Rana A, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transpl. 2008;8:2537–2546CrossRef
255.
Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55:965–967PubMedCrossRef
256.
Bernal W, Auzinger G, Sizer E, Wendon J. Intensive care management of acute liver failure. Semin Liver Dis. 2008;28:188–200PubMedCrossRef
257.
Karvellas CJ, Fix OK, Battenhouse H, Durkalski V, Sanders C, Lee WM, U S Acute Liver Failure Study Group. Outcomes and complications of intracranial pressure monitoring in acute liver failure: a retrospective cohort study. Crit Care Med. 2014;42:1157–1167.
258.
259.
Canalese J, Gimson AE, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut. 1982;23:625–629PubMedPubMedCentralCrossRef
260.
Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology. 2004;39:464–470PubMedCrossRef
261.
Qureshi AI, Suarez JI. Use of hypertonic saline solutions in treatment of cerebral edema and intracranial hypertension. Crit Care Med. 2000;28:3301–3313PubMedCrossRef
262.
The Brain Trauma Foundation, The American Association of Neurological Surgeons, The Joint Section on Neurotrauma and Critical Care. Guidelines for cerebral perfusion pressure. J Neurotrauma. 2000;17:507–511.
263.
Wakai A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury. Cochrane Database Syst Rev. 2007;1:CD001049.
264.
Slack AJ, Auzinger G, Willars C, Dew T, Musto R, Corsilli D, et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. 2014;34:42–48PubMedCrossRef
265.
Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64:69–78PubMedCrossRef
266.
Maiwall R, Bajpai M, Singh A, Agarwal T, Kumar G, Bharadwaj A, et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial. Clin Gastroenterol Hepatol. 2022;20:e831–e854PubMedCrossRef
267.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N, SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015;149:649–659.
268.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Mullhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X, SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–697.
269.
Younossi ZM, Stepanova M, Charlton M, Curry MP, O’Leary JG, Brown RS, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122–132PubMedCrossRef
270.
El-Sherif O, Jiang ZG, Tapper EB, Huang KC, Zhong A, Osinusi A, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection. Gastroenterology. 2018;154:2111-2121.e8PubMedCrossRef
271.
Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Tatsumi T, Ueno Y, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54:87–95PubMedCrossRef
272.
Verna EC, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73:540–548PubMedCrossRef
273.
Krassenburg LAP, Maan R, Ramji A, Manns MP, Cornberg M, Wedemeyer H, et al. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol. 2021;74:1053–1063PubMedCrossRef
274.
Pereira GH, Peixoto HR, Giusti ML, Souza ML, Victor LB, Fernandes F, et al. Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study. Braz J Infect Dis. 2022;26:102697PubMedPubMedCentralCrossRef
275.
Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C, European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65:524–531.
276.
Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65:777–788PubMedCrossRef
277.
Pageaux GP, Nzinga CL, Ganne N, Samuel D, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, de Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Riachi G, Alric L, Gelu-Simeon M, Minello A, Gournay J, Geist C, Tran A, Abergel A, Portal I, d'Alteroche L, Raffi F, Fontaine H, Carrat F, Pol S, French ANRS CO22 Hepather Cohort. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infect Dis. 2022;22:94.
278.
Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagiuoli S, Belli LS, European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver Int. 2018;38:2170–2177.
279.
Bittermann T, Reddy KR. In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent. Clin Gastroenterol Hepatol. 2021;19:2389-2397 e2382PubMedCrossRef
280.
Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir+/-dasabuvir+/-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat. 2017;24:936–943PubMedCrossRef
281.
Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017;67:32–39PubMedPubMedCentralCrossRef
282.
He S, Lockart I, Alavi M, Danta M, Hajarizadeh B, Dore GJ. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51:34–52PubMedCrossRef
283.
Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M, European Liver and Intestine Transplant Association (ELITA). The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities. J Viral Hepat. 2018;25:791–801.
284.
Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018;68:449–461PubMedCrossRef
285.
Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–832PubMedCrossRef
286.
Zaman A, Hapke R, Flora K, Rosen H, Benner K. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol. 1999;94:895–899PubMedCrossRef
287.
288.
Pagliaro L, D'Amico G, Sorensen TI, Lebrec D, Burroughs AK, Morabito A, Tine F, Politi F, Traina M. Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med. 1992;117:59–70.
289.
Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–1373PubMedCrossRef
290.
Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009;50:825–833PubMedCrossRef
291.
Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev. 2012;8:CD004544.
292.
Shah HA, Azam Z, Rauf J, Abid S, Hamid S, Jafri W, Khalid A, Ismail FW, Parkash O, Subhan A, Munir SM. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol. 2014;60:757–764.
293.
North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983–989.
294.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J, Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. J Hepatol. 2022;77:1014–1025.
295.
Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67:40–46PubMedCrossRef
296.
Onali S, Kalafateli M, Majumdar A, Westbrook R, O’Beirne J, Leandro G, et al. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver Int. 2017;37:1334–1344PubMedCrossRef
297.
Pérez-Ayuso RM, Piqué JM, Bosch J, Panés J, González A, Pérez R, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 1991;337:1431–1434PubMedCrossRef
298.
Tellez L, Ibanez-Samaniego L, Perez Del Villar C, Yotti R, Martinez J, Carrion L, Rodriguez de Santiago E, Rivera M, Gonzalez-Mansilla A, Pastor O, Bermejo J, Banares R, Albillos A. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol. 2020;73:1404–1414.
299.
Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol. 2020;72:463–471PubMedCrossRef
300.
Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Banares R, Albillos A. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149:109–122PubMedCrossRef
301.
Ravipati M, Katragadda S, Swaminathan PD, Molnar J, Zarling E. Pharmacotherapy plus endoscopic intervention is more effective than pharmacotherapy or endoscopy alone in the secondary prevention of esophageal variceal bleeding: a meta-analysis of randomized, controlled trials. Gastrointest Endosc. 2009;70:658-664.e5PubMedCrossRef
302.
Stanley AJ, Dickson S, Hayes PC, Forrest EH, Mills PR, Tripathi D, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol. 2014;61:1014–1019PubMedCrossRef
303.
Lo GH, Chen WC, Wang HM, Yu HC. Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. J Gastroenterol Hepatol. 2012;27:1681–1687PubMedCrossRef
304.
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, Hofer B, Pfisterer N, Schwarz M, Scheiner B, Stattermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis. Clin Gastroenterol Hepatol. 2022. https://​doi.​org/​10.​1016/​j.​cgh.​2022.​06.​007. Epub 2022 Jul 14.
305.
Sellers CM, Nezami N, Schilsky ML, Kim HS. Transjugular intrahepatic portosystemic shunt as a bridge to liver transplant: Current state and future directions. Transpl Rev (Orlando). 2019;33:64–71CrossRef
306.
Holster IL, Tjwa ET, Moelker A, Wils A, Hansen BE, Vermeijden JR, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + beta-blocker for prevention of variceal rebleeding. Hepatology. 2016;63:581–589PubMedCrossRef
307.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152:157–163PubMedCrossRef
308.
Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology. 1992;16:1343–1349PubMedCrossRef
309.
Mishra SR, Sharma BC, Kumar A, Sarin SK. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. J Hepatol. 2011;54:1161–1167PubMedCrossRef
310.
Rios Castellanos E, Seron P, Gisbert JP, Bonfill Cosp X. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. Cochrane Database Syst Rev. 2015;5:CD010180.
311.
Choe JW, Yim HJ, Lee SH, Chung HH, Lee YS, Kim SY, et al. Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation? Hepatol Int. 2021;15:934–945PubMedCrossRef
312.
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, et al. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7:736–746PubMedCrossRef
313.
Yu Q, Liu C, Raissi D. Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for gastric varices: a meta-analysis. J Clin Gastroenterol. 2021;55:147–158PubMedCrossRef
314.
Mishra SR, Chander Sharma B, Kumar A, Sarin SK. Endoscopic cyanoacrylate injection versus beta-blocker for secondary prophylaxis of gastric variceal bleed: a randomised controlled trial. Gut. 2010;59:729–735PubMedCrossRef
315.
Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007;39:679–685PubMedCrossRef
316.
Luo X, Xiang T, Wu J, Wang X, Zhu Y, Xi X, et al. Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial. Hepatology. 2021;74:2074–2084PubMedCrossRef
317.
Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch DB, Taichman DB, Horn EM, Zacks S, Kaplowitz N, Brown RS, Jr., Fallon MB, Pulmonary Vascular Complications of Liver Disease Study Group. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48:196–203.
318.
Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, C EH, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA, National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transpl. 2017;36:770–779.
319.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Radegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S, ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879.
320.
DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, et al. Predictors of waitlist mortality in portopulmonary hypertension. Transplantation. 2017;101:1609–1615PubMedPubMedCentralCrossRef
321.
Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–126PubMedCrossRef
322.
Wannhoff A, Hippchen T, Weiss CS, Friedrich K, Rupp C, Neumann-Haefelin C, et al. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. Aliment Pharmacol Ther. 2016;43:955–965PubMedCrossRef
323.
Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6:443–450PubMedCrossRef
324.
Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, et al. International liver transplant society practice guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation. 2016;100:1440–1452PubMedCrossRef
325.
Deroo R, Trépo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al. Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology. 2020;72:1701–1716PubMedCrossRef
326.
DeMartino ES, Cartin-Ceba R, Findlay JY, Heimbach JK, Krowka MJ. Frequency and outcomes of patients with increased mean pulmonary artery pressure at the time of liver transplantation. Transplantation. 2017;101:101–106PubMedCrossRef
327.
Sadd CJ, Osman F, Li Z, Chybowski A, Decker C, Henderson B, et al. Long-term outcomes and survival in moderate-severe portopulmonary hypertension after liver transplant. Transplantation. 2021;105:346–353PubMedCrossRef
328.
Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7:594–604PubMedCrossRef
329.
Nair S, Cohen DB, Cohen MP, Tan H, Maley W, Thuluvath PJ. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol. 2001;96:842–845PubMedCrossRef
330.
Hakeem AR, Cockbain AJ, Raza SS, Pollard SG, Toogood GJ, Attia MA, et al. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. Liver Transpl. 2013;19:551–562PubMedCrossRef
331.
Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O'Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S, European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019;71:313–322.
332.
Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016;63:1026–1040PubMedCrossRef
333.
Carias S, Castellanos AL, Vilchez V, Nair R, Dela Cruz AC, Watkins J, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol. 2016;31:628–633PubMedPubMedCentralCrossRef
334.
Tandon P, Ismond KP, Riess K, Duarte-Rojo A, Al-Judaibi B, Dunn MA, et al. Exercise in cirrhosis: translating evidence and experience to practice. J Hepatol. 2018;69:1164–1177PubMedCrossRef
335.
Lai JC, Sonnenday CJ, Tapper EB, Duarte-Rojo A, Dunn MA, Bernal W, et al. Frailty in liver transplantation: an expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice. Am J Transpl. 2019;19:1896–1906CrossRef
336.
Welch N, Dasarathy J, Runkana A, Penumatsa R, Bellar A, Reen J, et al. Continued muscle loss increases mortality in cirrhosis: impact of aetiology of liver disease. Liver Int. 2020;40:1178–1188PubMedPubMedCentralCrossRef
337.
Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schutz T, et al. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr. 2019;38:485–521PubMedPubMedCentralCrossRef
338.
Berzigotti A, Albillos A, Villanueva C, Genesca J, Ardevol A, Augustin S, Calleja JL, Banares R, Garcia-Pagan JC, Mesonero F, Bosch J, Ciberehd SportDiet Collaborative Group. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology. 2017;65:1293–1305.
339.
Pestana L, Swain J, Dierkhising R, Kendrick ML, Kamath PS, Watt KD. Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience. Mayo Clin Proc. 2015;90:209–215PubMedCrossRef
340.
Klebanoff MJ, Corey KE, Samur S, Choi JG, Kaplan LM, Chhatwal J, et al. Cost-effectiveness analysis of bariatric surgery for patients with nonalcoholic steatohepatitis cirrhosis. JAMA Netw Open. 2019;2:e190047PubMedPubMedCentralCrossRef
341.
Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:897–901PubMedCrossRef
342.
Zamora-Valdes D, Watt KD, Kellogg TA, Poterucha JJ, Di Cecco SR, Francisco-Ziller NM, et al. Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology. 2018;68:485–495PubMedCrossRef
343.
Wijarnpreecha K, Pungpapong S, Aby ES, Croome KP, Taner CB, Thompson CC, et al. Simultaneous liver transplant and sleeve gastrectomy not associated with worse index admission outcomes compared to liver transplant alone—a retrospective cohort study. Transpl Int. 2020;33:1447–1452PubMedCrossRef
344.
Gunturu NS, Castillo-Larios R, Bowers S, Edwards M, Burns J, Perry D, et al. Combined sleeve gastrectomy with liver transplant in patients with obesity: a feasibility study. Obes Surg. 2022;32:3600–3604PubMedCrossRef
345.
Vijayaraghavan R, Sarin SK, Bharadwaj A, Anand L, Maiwall R, Choudhury A, et al. Intragastric balloon in obese compensated nonalcoholic steatohepatitis cirrhosis patients is safe and achieves significant weight reduction at 6-months. Dig Dis Sci. 2023;68:1035–1041PubMedCrossRef
346.
Choudhary NS, Puri R, Saraf N, Saigal S, Kumar N, Rai R, et al. Intragastric balloon as a novel modality for weight loss in patients with cirrhosis and morbid obesity awaiting liver transplantation. Indian J Gastroenterol. 2016;35:113–116PubMedCrossRef
347.
Hibi T, Wei Chieh AK, Chi-Yan Chan A, Bhangui P. Current status of liver transplantation in Asia. Int J Surg. 2020;82S:4–8PubMedCrossRef
348.
Muthiah MD, Chua MSH, Griva K, Low I, Lim WH, Ng CH, et al. A multiethnic Asian perspective of presumed consent for organ donation: a population-based perception study. Front Public Health. 2021;9:712584PubMedPubMedCentralCrossRef
349.
Wijdicks EF, Varelas PN, Gronseth GS, Greer DM, American Academy of Neurology. Evidence-based guideline update: determining brain death in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1911–1918.
350.
Ploeg RJ, D’Alessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et al. Risk factors for primary dysfunction after liver transplantation—a multivariate analysis. Transplantation. 1993;55:807–813PubMedCrossRef
351.
Mor E, Klintmalm GB, Gonwa TA, Solomon H, Holman MJ, Gibbs JF, Watemberg I, Goldstein RM, Husberg BS. The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation. 1992;53:383–386.
352.
Wang Z, Hisatake G, Yang L. Liver-specific deceased donor risk indices. Hepatol Res. 2014;44:159–164PubMedCrossRef
353.
Zhou ZJ, Chen GS, Si ZZ, Li Q, Bin YY, Qi HZ, et al. Prognostic factors influencing outcome in adult liver transplantation using hypernatremic organ donation after brain death. Hepatobiliary Pancreat Dis Int. 2020;19:371–377PubMedCrossRef
354.
Akdur A, Ayvazoglu Soy HE, Karakaya E, Yildirim S, Moray G, Haberal M. Living and deceased liver donation criteria of Baskent University. Exp Clin Transpl. 2022;20:80–87CrossRef
355.
Hackl C, Schmidt KM, Susal C, Dohler B, Zidek M, Schlitt HJ. Split liver transplantation: current developments. World J Gastroenterol. 2018;24:5312–5321PubMedPubMedCentralCrossRef
356.
Chan KM, Hung HC, Lee JC, Wu TH, Wang YC, Cheng CH, et al. A review of split liver transplantation with full right/left hemi-liver grafts for 2 adult recipients. Medicine (Baltimore). 2021;100:e27369PubMedCrossRef
357.
Broering DC, Schulte am Esch J, Fischer L, Rogiers X. Split liver transplantation. HPB (Oxford). 2004;6:76–82.
358.
359.
Lee WC, Chan KM, Chou HS, Wu TJ, Lee CF, Soong RS, et al. Feasibility of split liver transplantation for 2 adults in the model of end-stage liver disease era. Ann Surg. 2013;258:306–311PubMedCrossRef
360.
Cherukuru R, Reddy MS, Shanmugam NP, Rajalingam R, Kota V, Gunasekaran V, et al. Feasibility and safety of split-liver transplantation in a nascent framework of deceased donation. Liver Transpl. 2019;25:450–458PubMedCrossRef
361.
Morrissey PE, Monaco AP. Donation after circulatory death: current practices, ongoing challenges, and potential improvements. Transplantation. 2014;97:258–264PubMedCrossRef
362.
Smith M, Dominguez-Gil B, Greer DM, Manara AR, Souter MJ. Organ donation after circulatory death: current status and future potential. Intensive Care Med. 2019;45:310–321PubMedCrossRef
363.
Ding GY, Zhao Y, Wu W, Zhong M, Fu PY, Xu M, et al. In situ normothermic regional perfusion for liver donation from china category III (organ donation after brain death followed by circulatory death): a single-center cohort study. Exp Clin Transpl. 2020;18:83–88CrossRef
364.
Thong WY, Chong PH, Koh PL, Loh WN, Tay SK. First pediatric organ donation after circulatory determination of death in Singapore: facing challenges in the absence of a local practice guideline. Pediatr Transpl. 2020;24:e13740CrossRef
365.
Kute V, Ramesh V, Shroff S, Guleria S, Prakash J. Deceased-donor organ transplantation in India: current status, challenges, and solutions. Exp Clin Transpl. 2020;18:31–42CrossRef
366.
Jeong E, Baik S, Park H, Oh J, Lee Y, Lee JM. First organ donation after circulatory death following withdrawal of life-sustaining treatment in korea: a case report. J Korean Med Sci. 2021;36:e171PubMedPubMedCentralCrossRef
367.
Rojas-Pena A, Sall LE, Gravel MT, Cooley EG, Pelletier SJ, Bartlett RH, et al. Donation after circulatory determination of death: the university of michigan experience with extracorporeal support. Transplantation. 2014;98:328–334PubMedCrossRef
368.
De Carlis R, Paolo M, Taner B. Donation after circulatory death: novel strategies to improve the liver transplant outcome. J Hepatol. 2023;78:1169–1180PubMedCrossRef
369.
Busquets J, Xiol X, Figueras J, Jaurrieta E, Torras J, Ramos E, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation. 2001;71:1765–1771PubMedCrossRef
370.
Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transpl. 2006;6:783–790CrossRef
371.
Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut. 2002;51:248–252PubMedPubMedCentralCrossRef
372.
Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl. 2008;14(Suppl 2):S45-50PubMedCrossRef
373.
Uemura T, Nikkel LE, Hollenbeak CS, Ramprasad V, Schaefer E, Kadry Z. How can we utilize livers from advanced aged donors for liver transplantation for hepatitis C? Transpl Int. 2012;25:671–679PubMedCrossRef
374.
Crespo G, Trota N, Londono MC, Mauro E, Baliellas C, Castells L, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol. 2018;69:11–17PubMedCrossRef
375.
Shaikh OS, Rogal S, Malik A, Sharma V, Cacciarelli T. Liver transplant from increased-risk donors in the era of direct-acting antivirals for hepatitis C. Exp Clin Transpl. 2020;18:605–611CrossRef
376.
Jimenez-Romero C, Justo I, Marcacuzco A, Garcia V, Manrique A, Garcia-Sesma A, et al. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study. Int J Surg. 2021;91:105981PubMedCrossRef
377.
Cescon M, Grazi GL, Cucchetti A, Ravaioli M, Ercolani G, Vivarelli M, et al. Improving the outcome of liver transplantation with very old donors with updated selection and management criteria. Liver Transpl. 2008;14:672–679PubMedCrossRef
378.
Selzner N, Selzner M, Jochum W, Amann-Vesti B, Graf R, Clavien PA. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol. 2006;44:694–701PubMedCrossRef
379.
Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16:874–884PubMedCrossRef
380.
Dutkowski P, Schlegel A, Slankamenac K, Oberkofler CE, Adam R, Burroughs AK, Schadde E, Mullhaupt B, Clavien PA. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256:861–868 (Discussion 868–869).
381.
Wong TC, Fung JY, Chok KS, Cheung TT, Chan AC, Sharr WW, et al. Excellent outcomes of liver transplantation using severely steatotic grafts from brain-dead donors. Liver Transpl. 2016;22:226–236PubMedCrossRef
382.
Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl. 2003;9:500–505PubMedCrossRef
383.
Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, et al. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002;73:1598–1602PubMedCrossRef
384.
Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272–279PubMedCrossRef
385.
Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts—a systematic analysis. Clin Transpl. 2011;25:E243-249CrossRef
386.
Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, Pinna AD, Avolio AW, Fagiuoli S, Burra P, Strazzabosco M, Costa AN, Liver Match Investigators. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013;58:715–723.
387.
Loggi E, Conti F, Cucchetti A, Ercolani G, Pinna AD, Andreone P. Liver grafts from hepatitis B surface antigen-positive donors: a review of the literature. World J Gastroenterol. 2016;22:8010–8016PubMedPubMedCentralCrossRef
388.
Yu S, Yu J, Zhang W, Cheng L, Ye Y, Geng L, et al. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation. J Hepatol. 2014;61:809–815PubMedCrossRef
389.
Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case–control study. Transplantation. 2011;91:1265–1272PubMedCrossRef
390.
Danford CJ, Redman JS, Alonso D. Hepatitis C-positive liver transplantation: outcomes and current practice. Curr Opin Organ Transpl. 2021;26:115–120CrossRef
391.
Lai JC, O'Leary JG, Trotter JF, Verna EC, Brown RS, Jr., Stravitz RT, Duman JD, Forman LM, Terrault NA, Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C). Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012;18:532–538.
392.
Bohorquez H, Bugeaud E, Bzowej N, Scheuermann J, Hand J, Bruce D, et al. Liver transplantation using hepatitis C virus-viremic donors into hepatitis C virus-aviremic recipients as standard of care. Liver Transpl. 2021;27:548–557PubMedCrossRef
393.
Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transpl. 2019;19:1380–1387CrossRef
394.
Boyarsky BJ, Hall EC, Singer AL, Montgomery RA, Gebo KA, Segev DL. Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transpl. 2011;11:1209–1217CrossRef
395.
Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation–results at 3 to 5 years. N Engl J Med. 2015;372:613–620PubMedPubMedCentralCrossRef
396.
Feng S, Buell JF, Chari RS, DiMaio JM, Hanto DW. Tumors and transplantation: the 2003 Third Annual ASTS State-of-the-Art Winter Symposium. Am J Transpl. 2003;3:1481–1487CrossRef
397.
Watson CJ, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transpl. 2010;10:1437–1444CrossRef
398.
Ikegami T, Shirabe K, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, et al. Strategies for successful left-lobe living donor liver transplantation in 250 consecutive adult cases in a single center. J Am Coll Surg. 2013;216:353–362PubMedCrossRef
399.
Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M. Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am J Transpl. 2005;5:1694–1703CrossRef
400.
Makuuchi M. Living donor liver transplantation: looking back at my 30 years of experience. Surg Today. 2019;49:288–294PubMedCrossRef
401.
Soejima Y, Shirabe K, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, et al. Left lobe living donor liver transplantation in adults. Am J Transpl. 2012;12:1877–1885CrossRef
402.
Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Harada N, Ijichi H, et al. Feasibility of left lobe living donor liver transplantation between adults: an 8-year, single-center experience of 107 cases. Am J Transpl. 2006;6:1004–1011CrossRef
403.
Takayama T, Makuuchi M, Kubota K, Sano K, Harihara Y, Kawarasaki H. Living-related transplantation of left liver plus caudate lobe. J Am Coll Surg. 2000;190:635–638PubMedCrossRef
404.
Fan ST, Lo CM, Liu CL, Wang WX, Wong J. Safety and necessity of including the middle hepatic vein in the right lobe graft in adult-to-adult live donor liver transplantation. Ann Surg. 2003;238:137–148PubMedPubMedCentralCrossRef
405.
Gyu Lee S, Min Park K, Hwang S, Hun Kim K, Nak Choi D, Hyung Joo S, et al. Modified right liver graft from a living donor to prevent congestion. Transplantation. 2002;74:54–59PubMedCrossRef
406.
Hwang S, Lee SG, Lee YJ, Sung KB, Park KM, Kim KH, et al. Lessons learned from 1000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl. 2006;12:920–927PubMedCrossRef
407.
Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. Am J Transpl. 2015;15:17–38CrossRef
408.
Cherqui D, Soubrane O, Husson E, Barshasz E, Vignaux O, Ghimouz M, et al. Laparoscopic living donor hepatectomy for liver transplantation in children. Lancet. 2002;359:392–396PubMedCrossRef
409.
Giulianotti PC, Tzvetanov I, Jeon H, Bianco F, Spaggiari M, Oberholzer J, et al. Robot-assisted right lobe donor hepatectomy. Transpl Int. 2012;25:e5-9PubMedCrossRef
410.
411.
Hong SK, Choe S, Yi NJ, Shin A, Choe EK, Yoon KC, et al. Long-term survival of 10,116 Korean live liver donors. Ann Surg. 2021;274:375–382PubMedCrossRef
412.
Miller CM, Durand F, Heimbach JK, Kim-Schluger L, Lee SG, Lerut J, et al. The international liver transplant society guideline on living liver donation. Transplantation. 2016;100:1238–1243PubMedCrossRef
413.
Soin AS, Chaudhary RJ, Pahari H, Pomfret EA. A worldwide survey of live liver donor selection policies at 24 centers with a combined experience of 19 009 adult living donor liver transplants. Transplantation. 2019;103:e39–e47PubMedCrossRef
414.
Kubota T, Hata K, Sozu T, Ueda Y, Hirao H, Okamura Y, et al. Impact of donor age on recipient survival in adult-to-adult living-donor liver transplantation. Ann Surg. 2018;267:1126–1133PubMedCrossRef
415.
Han JH, You YK, Na GH, Kim EY, Lee SH, Hong TH, et al. Outcomes of living donor liver transplantation using elderly donors. Ann Surg Treat Res. 2014;86:184–191PubMedPubMedCentralCrossRef
416.
Ikegami T, Taketomi A, Ohta R, Soejima Y, Yoshizumi T, Shimada M, et al. Donor age in living donor liver transplantation. Transpl Proc. 2008;40:1471–1475CrossRef
417.
Iwamoto T, Yagi T, Umeda Y, Sato D, Matsukawa H, Matsuda H, et al. The impact of donor age on the outcome of adult living donor liver transplantation. Transplantation. 2008;85:1240–1245PubMedCrossRef
418.
Kadohisa M, Inomata Y, Uto K, Hayashida S, Ohya Y, Yamamoto H, et al. Impact of donor age on the outcome of living-donor liver transplantation: special consideration to the feasibility of using elderly donors. Transplantation. 2021;105:328–337PubMedCrossRef
419.
Wang K, Jiang WT, Deng YL, Pan C, Shen ZY. Effect of donor age on graft function and long-term survival of recipients undergoing living donor liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14:50–55PubMedCrossRef
420.
Moss J, Lapointe-Rudow D, Renz JF, Kinkhabwala M, Dove LM, Gaglio PJ, et al. Select utilization of obese donors in living donor liver transplantation: implications for the donor pool. Am J Transpl. 2005;5:2974–2981CrossRef
421.
Andacoglu O, Tokat Y, Malamutmann E, Adali G, Emre A, Oezcelik A. Outcomes of right lobe donors with BMI>/=30 for living donor liver transplantation. Clin Transpl. 2022;36:e14698CrossRef
422.
Knaak M, Goldaracena N, Doyle A, Cattral MS, Greig PD, Lilly L, et al. Donor BMI >30 is not a contraindication for live liver donation. Am J Transpl. 2017;17:754–760CrossRef
423.
Takagi K, de Wilde RF, Polak WG, IJzermans JNM. The effect of donor body mass index on graft function in liver transplantation: a systematic review. Transpl Rev (Orlando). 2020;34:100571.
424.
Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. Korean society for the study of obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2018;2019(28):40–45
425.
Kasahara M, Sakamoto S, Horikawa R, Koji U, Mizuta K, Shinkai M, et al. Living donor liver transplantation for pediatric patients with metabolic disorders: the Japanese multicenter registry. Pediatr Transpl. 2014;18:6–15CrossRef
426.
Hwang S, Lee SG, Moon DB, Song GW, Ahn CS, Kim KH, et al. Exchange living donor liver transplantation to overcome ABO incompatibility in adult patients. Liver Transpl. 2010;16:482–490PubMed
427.
Jung DH, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Park GC, Lee SG. Section 16. Update on experience in paired-exchange donors in living donor liver transplantation for adult patients at ASAN Medical Center. Transplantation. 2014;97 Suppl 8:S66–69.
428.
Agrawal D, Saigal S, Jadaun SS, Singh SA, Agrawal S, Gupta S. Paired exchange living donor liver transplantation: a nine-year experience from North India. Transplantation. 2022;106:2193–2199PubMedCrossRef
429.
Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. Br J Surg. 2009;96:437–444PubMedCrossRef
430.
Hwang S, Lee SG, Jang SJ, Cho SH, Kim KH, Ahn CS, et al. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl. 2004;10:721–725PubMedCrossRef
431.
Oshita A, Tashiro H, Amano H, Kobayashi T, Onoe T, Ide K, et al. Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation. Transplantation. 2012;93:1024–1030PubMedCrossRef
432.
Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433–445PubMedCrossRef
433.
Simpson MA, Verbesey JE, Khettry U, Morin DS, Gordon FD, Burns DL, et al. Successful algorithm for selective liver biopsy in the right hepatic lobe live donor (RHLD). Am J Transpl. 2008;8:832–838CrossRef
434.
Fan ST, Lo CM, Liu CL, Yong BH, Chan JK, Ng IO. Safety of donors in live donor liver transplantation using right lobe grafts. Arch Surg. 2000;135:336–340PubMedCrossRef
435.
Taner CB, Dayangac M, Akin B, Balci D, Uraz S, Duran C, et al. Donor safety and remnant liver volume in living donor liver transplantation. Liver Transpl. 2008;14:1174–1179PubMedCrossRef
436.
Cho JY, Suh KS, Kwon CH, Yi NJ, Lee HH, Park JW, et al. Outcome of donors with a remnant liver volume of less than 35% after right hepatectomy. Liver Transpl. 2006;12:201–206PubMedCrossRef
437.
Kiuchi T, Tanaka K, Ito T, Oike F, Ogura Y, Fujimoto Y, et al. Small-for-size graft in living donor liver transplantation: how far should we go? Liver Transpl. 2003;9:S29-35PubMedCrossRef
438.
Sugawara Y, Makuuchi M, Takayama T, Imamura H, Dowaki S, Mizuta K, et al. Small-for-size grafts in living-related liver transplantation. J Am Coll Surg. 2001;192:510–513PubMedCrossRef
439.
Yi NJ, Suh KS, Lee HW, Shin WY, Kim J, Kim W, et al. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft. Liver Transpl. 2009;15:496–503PubMedCrossRef
440.
Alim A, Erdogan Y, Yuzer Y, Tokat Y, Oezcelik A. Graft-to-recipient weight ratio threshold adjusted to the model for end-stage liver disease score for living donor liver transplantation. Liver Transpl. 2016;22:1643–1648PubMedCrossRef
441.
Lee SD, Kim SH, Kim YK, Lee SA, Park SJ. Graft-to-recipient weight ratio lower to 0.7% is safe without portal pressure modulation in right-lobe living donor liver transplantation with favorable conditions. Hepatobiliary Pancreat Dis Int. 2014;13:18–24.
442.
Selzner M, Kashfi A, Cattral MS, Selzner N, Greig PD, Lilly L, McGilvray ID, Therapondos G, Adcock LE, Ghanekar A, Levy GA, Renner EL, Grant DR. A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. Liver Transpl. 2009;15:1776–1782.
443.
Wong TC, Fung JYY, Cui TYS, Sin SL, Ma KW, She BWH, et al. The risk of going small: lowering GRWR and overcoming small-for-size syndrome in adult living donor liver transplantation. Ann Surg. 2021;274:e1260–e1268PubMedCrossRef
444.
Kusakabe J, Yagi S, Sasaki K, Uozumi R, Abe H, Okamura Y, Taura K, Kaido T, Uemoto S. Is 0.6% reasonable as the minimum requirement of the graft-to-recipient weight ratio regardless of lobe selection in adult living-donor liver transplantation? Transplantation. 2021;105:2007–2017.
445.
Borhani AA, Elsayes KM, Catania R, Kambadakone A, Furlan A, Kierans AS, et al. Imaging evaluation of living liver donor candidates: techniques, protocols, and anatomy. Radiographics. 2021;41:1572–1591PubMedCrossRef
446.
Choi TW, Chung JW, Kim HC, Lee M, Choi JW, Jae HJ, et al. Anatomic variations of the hepatic artery in 5625 patients. Radiol Cardiothorac Imaging. 2021;3:e210007PubMedPubMedCentralCrossRef
447.
Malicki M, Marcinkowska W, Georgiev GP, Zielinska N, Olewnik L. Assessment of the incidence of accessory hepatic arteries: a literature review. Folia Morphol (Warsz). 2022;81:533–543PubMedCrossRef
448.
Noussios G, Dimitriou I, Chatzis I, Katsourakis A. The main anatomic variations of the hepatic artery and their importance in surgical practice: review of the literature. J Clin Med Res. 2017;9:248–252PubMedPubMedCentralCrossRef
449.
Schroering JR, Kubal CA, Fridell JA, Hathaway TJ, Robinson RC, Mangus RS. Impact of variant donor hepatic arterial anatomy on clinical graft outcomes in liver transplantation. Liver Transpl. 2018;24:1481–1484PubMedPubMedCentralCrossRef
450.
Zaki SM, Abdelmaksoud AHK, Khaled BEA, Abdel Kader IA. Anatomical variations of hepatic artery using the multidetector computed tomography angiography. Folia Morphol (Warsz). 2020;79:247–254PubMedCrossRef
451.
Iida T, Kaido T, Yagi S, Hori T, Uchida Y, Jobara K, et al. Hepatic arterial complications in adult living donor liver transplant recipients: a single-center experience of 673 cases. Clin Transpl. 2014;28:1025–1030CrossRef
452.
Sureka B, Patidar Y, Bansal K, Rajesh S, Agrawal N, Arora A. Portal vein variations in 1000 patients: surgical and radiological importance. Br J Radiol. 2015;88:20150326PubMedPubMedCentralCrossRef
453.
Takeishi K, Shirabe K, Yoshida Y, Tsutsui Y, Kurihara T, Kimura K, et al. Correlation between portal vein anatomy and bile duct variation in 407 living liver donors. Am J Transpl. 2015;15:155–160CrossRef
454.
Uchida K, Taniguchi M, Shimamura T, Suzuki T, Yamashita K, Ota M, et al. Three-dimensional computed tomography scan analysis of hepatic vasculatures in the donor liver for living donor liver transplantation. Liver Transpl. 2010;16:1062–1068PubMedCrossRef
455.
Ito K, Akamatsu N, Tani K, Ito D, Kaneko J, Arita J, et al. Reconstruction of hepatic venous tributary in right liver living donor liver transplantation: the importance of the inferior right hepatic vein. Liver Transpl. 2016;22:410–419PubMedCrossRef
456.
Guo HJ, Wang K, Chen KC, Liu ZK, Al-Ameri A, Shen Y, et al. Middle hepatic vein reconstruction in adult right lobe living donor liver transplantation improves recipient survival. Hepatobiliary Pancreat Dis Int. 2019;18:125–131PubMedCrossRef
457.
Nakamura T, Tanaka K, Kiuchi T, Kasahara M, Oike F, Ueda M, et al. Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. Transplantation. 2002;73:1896–1903PubMedCrossRef
458.
Chaib E, Kanas AF, Galvao FH, D’Albuquerque LA. Bile duct confluence: anatomic variations and its classification. Surg Radiol Anat. 2014;36:105–109PubMedCrossRef
459.
Song GW, Lee SG, Moon DB, Ahn CS, Hwang S, Kim KH, et al. Dual-graft adult living donor liver transplantation: an innovative surgical procedure for live liver donor pool expansion. Ann Surg. 2017;266:10–18PubMedCrossRef
460.
Soubrane O, de Rougemont O, Kim KH, Samstein B, Mamode N, Boillot O, Troisi RI, Scatton O, Cauchy F, Lee SG, Griesemer A, Ahmed Z, Clavien PA, Cherqui D. Laparoscopic living donor left lateral sectionectomy: a new standard practice for donor hepatectomy. Ann Surg. 2015;262:757–761 (Discussion 761–753).
461.
Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, et al. Impact of graft hepatic vein inferior vena cava reconstruction with graft venoplasty and inferior vena cava cavoplasty in living donor adult liver transplantation using a left lobe graft. Transplantation. 2005;80:964–968PubMedCrossRef
462.
Hwang S, Lee SG, Ha TY, Ahn CS, Park KM, Kim KH, et al. Simplified standardized technique for living donor liver transplantation using left liver graft plus caudate lobe. Liver Transpl. 2004;10:1398–1405PubMedCrossRef
463.
Cattral MS, Molinari M, Vollmer CM Jr, McGilvray I, Wei A, Walsh M, et al. Living-donor right hepatectomy with or without inclusion of middle hepatic vein: comparison of morbidity and outcome in 56 patients. Am J Transpl. 2004;4:751–757CrossRef
464.
Lo CM, Fan ST, Liu CL, Wei WI, Lo RJ, Lai CL, Chan JK, Ng IO, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg. 1997;226:261–269 (Discussion 269–270).
465.
Hwang S, Lee SG, Lee YJ, Park KM, Kim KH, Ahn CS, et al. Donor selection for procurement of right posterior segment graft in living donor liver transplantation. Liver Transpl. 2004;10:1150–1155PubMedCrossRef
466.
Kyoden Y, Tamura S, Sugawara Y, Akamatsu N, Matsui Y, Togashi J, et al. Biliary complications in right lateral sector graft live donor liver transplantation. Transpl Int. 2008;21:332–339PubMedCrossRef
467.
Sugawara Y, Makuuchi M, Takayama T, Imamura H, Kaneko J. Right lateral sector graft in adult living-related liver transplantation. Transplantation. 2002;73:111–114PubMedCrossRef
468.
Asonuma K, Shapiro AM, Inomata Y, Uryuhara K, Uemoto S, Tanaka K. Living related liver transplantation from donors with the left-sided gallbladder/portal vein anomaly. Transplantation. 1999;68:1610–1612PubMedCrossRef
469.
Hwang S, Lee SG, Park KM, Lee YJ, Ahn CS, Kim KH, et al. Hepatectomy of living donors with a left-sided gallbladder and multiple combined anomalies for adult-to-adult living donor liver transplantation. Liver Transpl. 2004;10:141–146PubMedCrossRef
470.
Gao Y, Wu W, Liu C, Liu T, Xiao H. Comparison of laparoscopic and open living donor hepatectomy: a meta-analysis. Medicine (Baltimore). 2021;100:e26708PubMedCrossRef
471.
Han HS, Cho JY, Kaneko H, Wakabayashi G, Okajima H, Uemoto S, et al. Expert panel statement on laparoscopic living donor hepatectomy. Dig Surg. 2018;35:284–288PubMedCrossRef
472.
Hong SK, Choi GS, Han J, Cho HD, Kim JM, Han YS, et al. Pure laparoscopic donor hepatectomy: a multicenter experience. Liver Transpl. 2021;27:67–76PubMedCrossRef
473.
Hong SK, Tan MY, Worakitti L, Lee JM, Cho JH, Yi NJ, et al. Pure laparoscopic versus open right hepatectomy in live liver donors: a propensity score-matched analysis. Ann Surg. 2022;275:e206–e212PubMedCrossRef
474.
Lai Q, Giovanardi F, Mennini G, Berardi G, Rossi M. The impact of mini-invasive right hepatectomy in the setting of living donation: a meta-analysis. Updates Surg. 2022;74:23–34PubMedCrossRef
475.
Rhu J, Choi GS, Kim JM, Kwon CHD, Joh JW. Complete transition from open surgery to laparoscopy: 8-year experience with more than 500 laparoscopic living donor hepatectomies. Liver Transpl. 2022;28:1158–1172PubMedCrossRef
476.
Soubrane O, Eguchi S, Uemoto S, Kwon CHD, Wakabayashi G, Han HS, et al. Minimally invasive donor hepatectomy for adult living donor liver transplantation: an international, multi-institutional evaluation of safety, efficacy and early outcomes. Ann Surg. 2022;275:166–174PubMedCrossRef
477.
Soubrane O, Perdigao Cotta F, Scatton O. Pure laparoscopic right hepatectomy in a living donor. Am J Transpl. 2013;13:2467–2471CrossRef
478.
Suh KS, Hong SK, Lee KW, Yi NJ, Kim HS, Ahn SW, et al. Pure laparoscopic living donor hepatectomy: focus on 55 donors undergoing right hepatectomy. Am J Transpl. 2018;18:434–443CrossRef
479.
Varghese CT, Chandran B, Sudhindran S. Robotic donor hepatectomy-safety in novelty is the essence. JAMA Surg. 2021;156:1171–1172PubMedCrossRef
480.
Chen PD, Wu CY, Hu RH, Ho CM, Lee PH, Lai HS, et al. Robotic liver donor right hepatectomy: a pure, minimally invasive approach. Liver Transpl. 2016;22:1509–1518PubMedCrossRef
481.
Rho SY, Lee JG, Joo DJ, Kim MS, Kim SI, Han DH, et al. Outcomes of robotic living donor right hepatectomy from 52 consecutive cases: comparison with open and laparoscopy-assisted donor hepatectomy. Ann Surg. 2022;275:e433–e442PubMedCrossRef
482.
Broering D, Sturdevant ML, Zidan A. Robotic donor hepatectomy: a major breakthrough in living donor liver transplantation. Am J Transpl. 2022;22:14–23CrossRef
483.
Schulze M, Elsheikh Y, Boehnert MU, Alnemary Y, Alabbad S, Broering DC. Robotic surgery and liver transplantation: a single-center experience of 501 robotic donor hepatectomies. Hepatobiliary Pancreat Dis Int. 2022;21:334–339PubMedCrossRef
484.
Lincango Naranjo EP, Garces-Delgado E, Siepmann T, Mirow L, Solis-Pazmino P, Alexander-Leon H, et al. Robotic living donor right hepatectomy: a systematic review and meta-analysis. J Clin Med. 2022;11:2603PubMedPubMedCentralCrossRef
485.
Middleton PF, Duffield M, Lynch SV, Padbury RT, House T, Stanton P, et al. Living donor liver transplantation–adult donor outcomes: a systematic review. Liver Transpl. 2006;12:24–30PubMedCrossRef
486.
Adcock L, Macleod C, Dubay D, Greig PD, Cattral MS, McGilvray I, et al. Adult living liver donors have excellent long-term medical outcomes: the University of Toronto liver transplant experience. Am J Transpl. 2010;10:364–371CrossRef
487.
Lauterio A, Di Sandro S, Gruttadauria S, Spada M, Di Benedetto F, Baccarani U, et al. Donor safety in living donor liver donation: an Italian multicenter survey. Liver Transpl. 2017;23:184–193PubMedCrossRef
488.
Lee JG, Lee KW, Kwon CHD, Chu CW, Kim BW, Choi DL, et al. Donor safety in living donor liver transplantation: the Korean organ transplantation registry study. Liver Transpl. 2017;23:999–1006PubMedCrossRef
489.
Acuna SA, Zhang W, Yoon PD, Ivanics T, Zhu MP, Claasen M, et al. Right lobe versus left lobe living donor liver transplantation: a systematic review and meta-analysis of donor and recipient outcomes. Transplantation. 2022;106:2370–2378PubMedCrossRef
490.
Broering DC, Elsheikh Y, Alnemary Y, Zidan A, Elsarawy A, Saleh Y, et al. Robotic versus open right lobe donor hepatectomy for adult living donor liver transplantation: a propensity score-matched analysis. Liver Transpl. 2020;26:1455–1464PubMedCrossRef
491.
Rhu J, Kim MS, Choi GS, Kim JM, Kwon CHD, Joh JW. Laparoscopic living donor right hepatectomy regarding the anatomical variation of the portal vein: a propensity score-matched analysis. Liver Transpl. 2021;27:984–996PubMedCrossRef
492.
Yeow M, Soh S, Starkey G, Perini MV, Koh YX, Tan EK, et al. A systematic review and network meta-analysis of outcomes after open, mini-laparotomy, hybrid, totally laparoscopic, and robotic living donor right hepatectomy. Surgery. 2022;172:741–750PubMedCrossRef
493.
Kwong AJ, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2019 annual data report: liver. Am J Transpl. 2021;21(Suppl 2):208–315CrossRef
494.
Shaw BW Jr, Martin DJ, Marquez JM, Kang YG, Bugbee AC Jr, Iwatsuki S, et al. Venous bypass in clinical liver transplantation. Ann Surg. 1984;200:524–534PubMedPubMedCentralCrossRef
495.
Starzl TE, Iwatsuki S, Esquivel CO, Todo S, Kam I, Lynch S, et al. Refinements in the surgical technique of liver transplantation. Semin Liver Dis. 1985;5:349–356PubMedPubMedCentralCrossRef
496.
Khorsandi SE, Athale A, Vilca-Melendez H, Jassem W, Prachalias A, Srinivasan P, et al. Presentation, diagnosis, and management of early hepatic venous outflow complications in whole cadaveric liver transplant. Liver Transpl. 2015;21:914–921PubMedCrossRef
497.
498.
Hesse UJ, Berrevoet F, Troisi R, Pattyn P, Mortier E, Decruyenaere J, et al. Hepato-venous reconstruction in orthotopic liver transplantation with preservation of the recipients’ inferior vena cava and veno-venous bypass. Langenbecks Arch Surg. 2000;385:350–356PubMedCrossRef
499.
Belghiti J, Panis Y, Sauvanet A, Gayet B, Fekete F. A new technique of side to side caval anastomosis during orthotopic hepatic transplantation without inferior vena caval occlusion. Surg Gynecol Obstet. 1992;175:270–272PubMed
500.
Cherqui D, Lauzet JY, Rotman N, Duvoux C, Dhumeaux D, Julien M, Fagniez PL. Orthotopic liver transplantation with preservation of the caval and portal flows. Technique and results in 62 cases. Transplantation. 1994;58:793–796.
501.
Jovine E, Mazziotti A, Grazi GL, Ercolani G, Masetti M, Morganti M, et al. Piggy-back versus conventional technique in liver transplantation: report of a randomized trial. Transpl Int. 1997;10:109–112PubMedCrossRef
502.
Stieber AC. One surgeon’s experience with the piggyback versus the standard technique in orthotopic liver transplantation: is one better than the other? Hepatogastroenterology. 1995;42:403–405PubMed
503.
Shaker TM, Eason JD, Davidson BR, Barth RN, Pirenne J, Imventarza O, Spiro M, Raptis DA, Fung J, ERAS4OLT.org Working Group. Which cava anastomotic techniques are optimal regarding immediate and short-term outcomes after liver transplantation: A systematic review of the literature and expert panel recommendations. Clin Transplant. 2022;36:e14681.
504.
Gurusamy KS, Koti R, Pamecha V, Davidson BR. Veno-venous bypass versus none for liver transplantation. Cochrane Database Syst Rev. 2011;3:CD007712.
505.
Czigany Z, Scherer MN, Pratschke J, Guba M, Nadalin S, Mehrabi A, et al. Technical aspects of orthotopic liver transplantation-a survey-based study within the eurotransplant, swisstransplant, scandiatransplant, and british transplantation society networks. J Gastrointest Surg. 2019;23:529–537PubMedCrossRef
506.
Pratschke S, Rauch A, Albertsmeier M, Rentsch M, Kirschneck M, Andrassy J, et al. Temporary intraoperative porto-caval shunts in piggy-back liver transplantation reduce intraoperative blood loss and improve postoperative transaminases and renal function: a meta-analysis. World J Surg. 2016;40:2988–2998PubMedCrossRef
507.
Bhangui P, Fernandes ESM, Di Benedetto F, Joo DJ, Nadalin S. Current management of portal vein thrombosis in liver transplantation. Int J Surg. 2020;82S:122–127PubMedCrossRef
508.
Koh PS, Chan SC, Chok KS, Sharr WW, Wong TC, Sin SL, et al. The friendly incidental portal vein thrombus in liver transplantation. Liver Transpl. 2015;21:944–952PubMedCrossRef
509.
Miura K, Sugawara Y, Uchida K, Kawabata S, Yoshii D, Isono K, et al. Adult living donor liver transplantation for patients with portal vein thrombosis: a single-center experience. Transpl Direct. 2018;4:e341CrossRef
510.
Bhangui P, Lim C, Levesque E, Salloum C, Lahat E, Feray C, et al. Novel classification of non-malignant portal vein thrombosis: a guide to surgical decision-making during liver transplantation. J Hepatol. 2019;71:1038–1050PubMedCrossRef
511.
Czerniak A, Badger I, Sherlock D, Buckels J. Orthotopic liver transplantation in a patient with thrombosis of the hepatic portal and superior mesenteric veins. Transplantation. 1990;50:334–336PubMed
512.
Hiatt JR, Quinones-Baldrich WJ, Ramming KP, Lois JF, Busuttil RW. Bile duct varices. An alternative to portoportal anastomosis in liver transplantation. Transplantation. 1986;42:85.
513.
Langnas AN, Marujo WC, Stratta RJ, Wood RP, Ranjan D, Ozaki C, et al. A selective approach to preexisting portal vein thrombosis in patients undergoing liver transplantation. Am J Surg. 1992;163:132–136PubMedCrossRef
514.
Moon DB, Lee SG, Ahn CS, Kim KH, Hwang S, Ha TY, et al. Technical modification of reno-portal anastomosis in living donor liver transplantation for patients with obliterated portal vein and large spontaneous splenorenal shunts. Hepatogastroenterology. 2008;55:2193–2199PubMed
515.
Slooff MJ. Reduced size liver transplantation, split liver transplantation, and living related liver transplantation in relation to the donor organ shortage. Transpl Int. 1995;8:65–68PubMedCrossRef
516.
Pichlmayr R, Ringe B, Gubernatis G, Hauss J. Bunzendahl H [Transplantation of a donor liver to 2 recipients (splitting transplantation)—a new method in the further development of segmental liver transplantation]. Langenbecks Arch Chir. 1988;373:127–130PubMedCrossRef
517.
Rogiers X, Malago M, Gawad KA, Kuhlencordt R, Froschle G, Sturm E, Sterneck M, Pothmann W, Schulte am Esch J, Burdelski M, Broelsch C. One year of experience with extended application and modified techniques of split liver transplantation. Transplantation. 1996;61:1059–1061.
518.
Lodge JP, Dasgupta D, Prasad KR, Attia M, Toogood GJ, Davies M, et al. Emergency subtotal hepatectomy: a new concept for acetaminophen-induced acute liver failure: temporary hepatic support by auxiliary orthotopic liver transplantation enables long-term success. Ann Surg. 2008;247:238–249PubMedCrossRef
519.
Hwang S, Ha TY, Ahn CS, Moon DB, Kim KH, Song GW, et al. Standardized surgical techniques for adult living donor liver transplantation using a modified right lobe graft: a video presentation from bench to reperfusion. Korean J Hepatobiliary Pancreat Surg. 2016;20:97–101PubMedPubMedCentralCrossRef
520.
Takatsuki M, Soyama A, Hidaka M, Kinoshita A, Baimakhanov Z, Kugiyama T, et al. Technical refinement of hepatic vein reconstruction in living donor liver transplantation using left liver graft. Ann Transpl. 2015;20:290–296CrossRef
521.
Balci D, Kirimker EO. Hepatic vein in living donor liver transplantation. Hepatobiliary Pancreat Dis Int. 2020;19:318–323PubMedCrossRef
522.
Lee JM, Lee KW. Techniques for overcoming atretic changes of the portal vein in living donor liver transplantation. Hepatobiliary Pancreat Dis Int. 2020;19:311–317PubMedCrossRef
523.
Hwang S, Ha TY, Song GW, Jung DH, Moon DB, Ahn CS, et al. Conjoined unification venoplasty for double portal vein branches of right liver graft: 1-year experience at a high-volume living donor liver transplantation center. J Gastrointest Surg. 2016;20:199–205PubMedCrossRef
524.
Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, et al. Technique and outcome of autologous portal Y-graft interposition for anomalous right portal veins in living donor liver transplantation. Liver Transpl. 2009;15:427–434PubMedCrossRef
525.
Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transpl. 2005;5:2605–2610CrossRef
526.
Yoshizumi T, Mori M. Portal flow modulation in living donor liver transplantation: review with a focus on splenectomy. Surg Today. 2020;50:21–29PubMedCrossRef
527.
Etesami K, Genyk Y. The increasingly limited basis for portal venous pressure modulation in living donor liver transplantation. Liver Transpl. 2018;24:1506–1507PubMedCrossRef
528.
Masuda Y, Yoshizawa K, Ohno Y, Mita A, Shimizu A, Soejima Y. Small-for-size syndrome in liver transplantation: definition, pathophysiology and management. Hepatobiliary Pancreat Dis Int. 2020;19:334–341PubMedCrossRef
529.
Troisi RI, Berardi G, Tomassini F, Sainz-Barriga M. Graft inflow modulation in adult-to-adult living donor liver transplantation: a systematic review. Transpl Rev (Orlando). 2017;31:127–135CrossRef
530.
Fayed N, Refaat EK, Yassein TE, Alwaraqy M. Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation. J Crit Care. 2013;28:775–782PubMedCrossRef
531.
Troisi RI, Vanlander A, Giglio MC, Van Limmen J, Scudeller L, Heyse B, et al. Somatostatin as inflow modulator in liver-transplant recipients with severe portal hypertension: a randomized trial. Ann Surg. 2019;269:1025–1033PubMedCrossRef
532.
Ito K, Akamatsu N, Ichida A, Ito D, Kaneko J, Arita J, et al. Splenectomy is not indicated in living donor liver transplantation. Liver Transpl. 2016;22:1526–1535PubMedCrossRef
533.
Rammohan A, Rela M, Kim DS, Soejima Y, Kasahara M, Ikegami T, Spiro M, Aristotle Raptis D, Humar A, ERAS4OLT.org Working Group. Does modification of portal pressure and flow enhance recovery of the recipient after living donor liver transplantation? A systematic review of literature and expert panel recommendations. Clin Transplant. 2022;36:e14657.
534.
Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, Kayashima H, et al. The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. Transpl Int. 2008;21:833–842PubMedCrossRef
535.
Boillot O, Delafosse B, Mechet I, Boucaud C, Pouyet M. Small-for-size partial liver graft in an adult recipient; a new transplant technique. Lancet. 2002;359:406–407PubMedCrossRef
536.
Sato Y, Yamamoto S, Takeishi T, Kato T, Nakatsuka H, Kobayashi T, et al. Inferior mesenteric venous left renal vein shunting for decompression of excessive portal hypertension in adult living related liver transplantation. Transpl Proc. 2004;36:2234–2236CrossRef
537.
Troisi R, Ricciardi S, Smeets P, Petrovic M, Van Maele G, Colle I, et al. Effects of hemi-portocaval shunts for inflow modulation on the outcome of small-for-size grafts in living donor liver transplantation. Am J Transpl. 2005;5:1397–1404CrossRef
538.
Yamada T, Tanaka K, Uryuhara K, Ito K, Takada Y, Uemoto S. Selective hemi-portocaval shunt based on portal vein pressure for small-for-size graft in adult living donor liver transplantation. Am J Transpl. 2008;8:847–853CrossRef
539.
Asencio JM, Vaquero J, Olmedilla L, Garcia Sabrido JL. “Small-for-flow” syndrome: shifting the “size” paradigm. Med Hypotheses. 2013;80:573–577PubMedCrossRef
540.
Jo HS, Yu YD, Choi YJ, Kim DS. Left liver graft in adult-to-adult living donor liver transplantation with an optimal portal flow modulation strategy to overcome the small-for-size syndrome—a retrospective cohort study. Int J Surg. 2022;106:106953PubMedCrossRef
541.
Ahn CS, Hwang S, Moon DB, Song GW, Ha TY, Park GC, et al. Right gastroepiploic artery is the first alternative inflow source for hepatic arterial reconstruction in living donor liver transplantation. Transpl Proc. 2012;44:451–453CrossRef
542.
Lee JH, Oh DY, Seo JW, Moon SH, Rhie JW, Ahn ST. Versatility of right gastroepiploic and gastroduodenal arteries for arterial reconstruction in adult living donor liver transplantation. Transpl Proc. 2011;43:1716–1719CrossRef
543.
Uchiyama H, Shirabe K, Taketomi A, Soejima Y, Ninomiya M, Kayashima H, et al. Extra-anatomical hepatic artery reconstruction in living donor liver transplantation: can this procedure save hepatic grafts? Liver Transpl. 2010;16:1054–1061PubMedCrossRef
544.
Jung DH, Ikegami T, Balci D, Bhangui P. Biliary reconstruction and complications in living donor liver transplantation. Int J Surg. 2020;82S:138–144PubMedCrossRef
545.
Sugawara Y, Makuuchi M, Sano K, Ohkubo T, Kaneko J, Takayama T. Duct-to-duct biliary reconstruction in living-related liver transplantation. Transplantation. 2002;73:1348–1350PubMedCrossRef
546.
Kawagishi N, Takeda I, Miyagi S, Satoh K, Akamatsu Y, Sekiguchi S, et al. Long-term outcome of ABO-incompatible living-donor liver transplantation: a single-center experience. J Hepatobiliary Pancreat Surg. 2009;16:468–472PubMedCrossRef
547.
Kim JD, Choi DL, Kim SG, Lee AJ. Single-center experience of ABO-incompatible living-donor liver transplantation with a new simplified intravenous immunoglobulin protocol: a propensity score-matching analysis. Transpl Proc. 2016;48:1134–1138CrossRef
548.
Lee J, Lee JG, Lee JJ, Kim MS, Ju MK, Choi GH, et al. Results of ABO-incompatible liver transplantation using a simplified protocol at a single institution. Transpl Proc. 2015;47:723–726CrossRef
549.
550.
Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology. 2008;47:143–152PubMedCrossRef
551.
Han CZ, Wei Q, Yang MF, Zhuang L, Xu X. The critical role of therapeutic plasma exchange in ABO-incompatible liver transplantation. Hepatobiliary Pancreat Dis Int. 2022;21:538–542PubMedCrossRef
552.
Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Harada N, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Transplantation. 2009;88:303–307PubMedCrossRef
553.
Song GW, Lee SG, Hwang S, Kim KH, Ahn CS, Moon DB, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transpl. 2016;16:157–170CrossRef
554.
Yadav DK, Hua YF, Bai X, Lou J, Que R, Gao S, et al. ABO-incompatible adult living donor liver transplantation in the era of rituximab: a systematic review and meta-analysis. Gastroenterol Res Pract. 2019;2019:8589402PubMedPubMedCentralCrossRef
555.
O’Brien J, Buckley AR, Browne R. Comprehensive ultrasound assessment of complications post-liver transplantation. Eur J Radiol. 2010;74:206–213PubMedCrossRef
556.
557.
Pfau PR, Kochman ML, Lewis JD, Long WB, Lucey MR, Olthoff K, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc. 2000;52:55–63PubMedCrossRef
558.
Balci D, Ahn CS. Hepatic artery reconstruction in living donor liver transplantation. Curr Opin Organ Transplant. 2019;24:631–636PubMedCrossRef
559.
Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, et al. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014;20:1221–1228PubMedPubMedCentralCrossRef
560.
Li H, Li B, Wei Y, Yan L, Wen T, Wang W, et al. Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: a single center 12-year experience. Clin Res Hepatol Gastroenterol. 2015;39:451–457PubMedCrossRef
561.
Lin TS, Chiang YC, Chen CL, Concejero AM, Cheng YF, Wang CC, et al. Intimal dissection of the hepatic artery following transarterial embolization for hepatocellular carcinoma: an intraoperative problem in adult living donor liver transplantation. Liver Transpl. 2009;15:1553–1556PubMedCrossRef
562.
Panaro F, Ramos J, Gallix B, Mercier G, Herrero A, Niampa H, Pageaux GP, Navarro F. Hepatic artery complications following liver transplantation. Does preoperative chemoembolization impact the postoperative course? Clin Transplant. 2014;28:598–605.
563.
Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, et al. Treatment of hepatitis C in renal transplantation candidates: a single-center experience. Transplantation. 2010;90:407–411PubMedCrossRef
564.
Wu L, Zhang J, Guo Z, Tai Q, He X, Ju W, et al. Hepatic artery thrombosis after orthotopic liver transplant: a review of the same institute 5 years later. Exp Clin Transpl. 2011;9:191–196
565.
Panpikoon T, Treesit T, Bua-Ngam C, Feinggumloon S, Pichitpichatkul K, Sriprachyakul A, Aimprasittichai S, Chimcherd A, Thirapattaraphan C, Lertudomphonwanit C, Tanpowpong P. Early postoperative duplex ultrasound findings of the hepatic artery in postoperative vascular complications from paediatric liver transplantation. J Ultrasound. 2022. https://​doi.​org/​10.​1007/​s40477-022-00738-4. Epub 2022/10/21.
566.
Wakiya T, Sanada Y, Mizuta K, Umehara M, Urahashi T, Egami S, et al. Endovascular interventions for hepatic artery complications immediately after pediatric liver transplantation. Transpl Int. 2011;24:984–990PubMedCrossRef
567.
Pereira K, Salsamendi J, Dalal R, Quintana D, Bhatia S, Fan J. Percutaneous endovascular therapeutic options in treating posttransplant hepatic artery thrombosis with the aim of salvaging liver allografts: our experience. Exp Clin Transpl. 2016;14:542–550
568.
Alfares BA, Bokkers RPH, Verkade HJ, Dierckx R, Gupte G, Franchi-Abella S, et al. Portal vein obstruction after pediatric liver transplantation: a systematic review of current treatment strategies. Transpl Rev (Orlando). 2021;35:100630CrossRef
569.
Egawa H, Tanaka K, Kasahara M, Takada Y, Oike F, Ogawa K, et al. Single center experience of 39 patients with preoperative portal vein thrombosis among 404 adult living donor liver transplantations. Liver Transpl. 2006;12:1512–1518PubMedCrossRef
570.
Kyoden Y, Tamura S, Sugawara Y, Matsui Y, Togashi J, Kaneko J, et al. Portal vein complications after adult-to-adult living donor liver transplantation. Transpl Int. 2008;21:1136–1144PubMedCrossRef
571.
Ma L, Lu Q, Luo Y. Vascular complications after adult living donor liver transplantation: Evaluation with ultrasonography. World J Gastroenterol. 2016;22:1617–1626PubMedPubMedCentralCrossRef
572.
Sambommatsu Y, Shimata K, Ibuki S, Narita Y, Isono K, Honda M, et al. Portal vein complications after adult living donor liver transplantation: time of onset and deformity patterns affect long-term outcomes. Liver Transpl. 2021;27:854–865PubMedCrossRef
573.
Mourad MM, Liossis C, Gunson BK, Mergental H, Isaac J, Muiesan P, et al. Etiology and management of hepatic artery thrombosis after adult liver transplantation. Liver Transpl. 2014;20:713–723PubMedCrossRef
574.
Hashimoto T, Sugawara Y, Tamura S, Kaneko J, Motomura N, Takamoto S, et al. One orifice vein reconstruction in left liver plus caudate lobe grafts. Transplantation. 2007;83:225–227PubMedCrossRef
575.
Lee S, Hwang S, Park K, Lee Y, Choi D, Ahn C, et al. An adult-to-adult living donor liver transplant using dual left lobe grafts. Surgery. 2001;129:647–650PubMedCrossRef
576.
Makuuchi M, Sugawara Y. Living-donor liver transplantation using the left liver, with special reference to vein reconstruction. Transplantation. 2003;75:S23-24PubMedCrossRef
577.
Sugawara Y, Makuuchi M, Akamatsu N, Kishi Y, Niiya T, Kaneko J, et al. Refinement of venous reconstruction using cryopreserved veins in right liver grafts. Liver Transpl. 2004;10:541–547PubMedCrossRef
578.
Hwang HJ, Kim KW, Jeong WK, Song GW, Ko GY, Sung KB, et al. Right hepatic vein stenosis at anastomosis in patients after living donor liver transplantation: optimal Doppler US venous pulsatility index and CT criteria–receiver operating characteristic analysis. Radiology. 2009;253:543–551PubMedCrossRef
579.
Umehara M, Narumi S, Sugai M, Toyoki Y, Ishido K, Kudo D, et al. Hepatic venous outflow obstruction in living donor liver transplantation: balloon angioplasty or stent placement? Transpl Proc. 2012;44:769–771CrossRef
580.
Fasullo M, Patel M, Khanna L, Shah T. Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment. BMJ Open Gastroenterol. 2022;9:e000778PubMedPubMedCentralCrossRef
581.
Jagannath S, Kalloo AN. Biliary complications after liver transplantation. Curr Treat Options Gastroenterol. 2002;5:101–112PubMedCrossRef
582.
Thuluvath PJ, Atassi T, Lee J. An endoscopic approach to biliary complications following orthotopic liver transplantation. Liver Int. 2003;23:156–162PubMedCrossRef
583.
Akamatsu N, Sugawara Y, Hashimoto D. Biliary reconstruction, its complications and management of biliary complications after adult liver transplantation: a systematic review of the incidence, risk factors and outcome. Transpl Int. 2011;24:379–392PubMedCrossRef
584.
Baccarani U, Risaliti A, Zoratti L, Zilli M, Brosola P, Vianello V, et al. Role of endoscopic retrograde cholangiopancreatography in the diagnosis and treatment of biliary tract complications after orthotopic liver transplantation. Dig Liver Dis. 2002;34:582–586PubMedCrossRef
585.
Macias-Gomez C, Dumonceau JM. Endoscopic management of biliary complications after liver transplantation: an evidence-based review. World J Gastrointest Endosc. 2015;7:606–616PubMedPubMedCentralCrossRef
586.
Verdonk RC, Buis CI, Porte RJ, van der Jagt EJ, Limburg AJ, van den Berg AP, et al. Anastomotic biliary strictures after liver transplantation: causes and consequences. Liver Transpl. 2006;12:726–735PubMedCrossRef
587.
Buis CI, Verdonk RC, Van der Jagt EJ, van der Hilst CS, Slooff MJ, Haagsma EB, Porte RJ. Nonanastomotic biliary strictures after liver transplantation, part 1: radiological features and risk factors for early vs. late presentation. Liver Transpl. 2007;13:708–718.
588.
Amer A, McColl K, Bouayyad S, Kanwar A, Sen G, French JJ, et al. The association of pregnane X receptor activation with outcomes after liver transplantation—a retrospective study. Clin Transpl. 2019;33:e13734CrossRef
589.
Iacob S, Cicinnati VR, Dechene A, Lindemann M, Heinemann FM, Rebmann V, et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int. 2012;32:1253–1261PubMedCrossRef
590.
Koneru B, Sterling MJ, Bahramipour PF. Bile duct strictures after liver transplantation: a changing landscape of the Achilles’ heel. Liver Transpl. 2006;12:702–704PubMedCrossRef
591.
Magro B, Tacelli M, Mazzola A, Conti F, Celsa C. Biliary complications after liver transplantation: current perspectives and future strategies. Hepatobiliary Surg Nutr. 2021;10:76–92PubMedPubMedCentralCrossRef
592.
Huh K, Jeong SJ, Kim YJ, Kang JM, Kim JM, Park WB, et al. Nationwide survey of infection prevention protocols in solid organ transplantation in South Korea. Korean J Transpl. 2022;36:212–220CrossRef
593.
Iinuma Y, Senda K, Fujihara N, Saito T, Takakura S, Kudo T, et al. Surgical site infection in living-donor liver transplant recipients: a prospective study. Transplantation. 2004;78:704–709PubMedCrossRef
594.
Arnow PM, Furmaga K, Flaherty JP, George D. Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients. Antimicrob Agents Chemother. 1992;36:2125–2130PubMedPubMedCentralCrossRef
595.
Bedini A, Codeluppi M, Cocchi S, Guaraldi G, Di Benedetto F, Venturelli C, et al. Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survival. Transpl Proc. 2007;39:1947–1949CrossRef
596.
Asensio A, Ramos A, Cuervas-Mons V, Cordero E, Sanchez-Turrion V, Blanes M, et al. Effect of antibiotic prophylaxis on the risk of surgical site infection in orthotopic liver transplant. Liver Transpl. 2008;14:799–805PubMedCrossRef
597.
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA, American Society of Health-System Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), Surgical Infection Society (SIS), Society for Healthcare Epidemiology of America (SHEA). Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14:73–156.
598.
Bandali A, Bias TE, Lee DH, Malat G. Duration of perioperative antimicrobial prophylaxis in orthotopic liver transplantation patients. Prog Transpl. 2020;30:265–270CrossRef
599.
Berry PS, Rosenberger LH, Guidry CA, Agarwal A, Pelletier S, Sawyer RG. Intraoperative versus extended antibiotic prophylaxis in liver transplant surgery: a randomized controlled pilot trial. Liver Transpl. 2019;25:1043–1053PubMedCrossRef
600.
Kotton CN. CMV: Prevention, diagnosis and therapy. Am J Transpl. 2013;13 Suppl 3:24–40 (quiz 40).
601.
602.
Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection after transplantation. Drugs. 2018;78:1085–1103PubMedCrossRef
603.
604.
Stern M, Hirsch H, Cusini A, van Delden C, Manuel O, Meylan P, Boggian K, Mueller NJ, Dickenmann M, Members of Swiss Transplant Cohort Study. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98:1013–1018.
605.
Vutien P, Perkins J, Biggins SW, Reyes J, Imlay H, Limaye AP. Association of donor and recipient cytomegalovirus serostatus on graft and patient survival in liver transplant recipients. Liver Transpl. 2021;27:1302–1311PubMedPubMedCentralCrossRef
606.
Diaz-Pedroche C, Lumbreras C, San Juan R, Folgueira D, Andres A, Delgado J, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation. 2006;82:30–35PubMedCrossRef
607.
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13512CrossRef
608.
Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, et al. Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020;323:1378–1387PubMedPubMedCentralCrossRef
609.
Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transpl. 2008;8:158–161CrossRef
610.
Amorim ML, Cabeda JM, Seca R, Mendes AC, Castro AP, Amorim JM. CMV infection of liver transplant recipients: comparison of antigenemia and molecular biology assays. BMC Infect Dis. 2001;1:2PubMedPubMedCentralCrossRef
611.
Kamei H, Ito Y, Onishi Y, Suzuki M, Imai H, Kurata N, et al. Cytomegalovirus (CMV) monitoring after liver transplantation: comparison of CMV Pp65 antigenemia assay with real-time PCR calibrated to WHO international standard. Ann Transpl. 2016;21:131–136CrossRef
612.
Hadley S, Huckabee C, Pappas PG, Daly J, Rabkin J, Kauffman CA, et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis. 2009;11:40–48PubMedCrossRef
613.
Singh N. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design. Clin Infect Dis. 2004;39(Suppl 4):S200-206PubMedCrossRef
614.
Gavalda J, Len O, San Juan R, Aguado JM, Fortun J, Lumbreras C, Moreno A, Munoz P, Blanes M, Ramos A, Rufi G, Gurgui M, Torre-Cisneros J, Montejo M, Cuenca-Estrella M, Rodriguez-Tudela JL, Pahissa A, RESITRA (Spanish Network for Research on Infection in Transplantation). Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case–control study. Clin Infect Dis. 2005;41:52–59.
615.
616.
Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc. 1995;106:38–47 (Discussion 47–48).
617.
Saliba F, Delvart V, Ichai P, Kassis N, Botterel F, Mihaila L, et al. Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era. Clin Transpl. 2013;27:E454-461CrossRef
618.
Biancofiore G, Bindi ML, Baldassarri R, Romanelli AM, Catalano G, Filipponi F, et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int. 2002;15:341–347PubMedCrossRef
619.
Eschenauer GA, Kwak EJ, Humar A, Potoski BA, Clarke LG, Shields RK, et al. Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transpl. 2015;15:180–189CrossRef
620.
Singhal S, Ellis RW, Jones SG, Miller SJ, Fisher NC, Hastings JG, et al. Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transpl. 2000;6:588–595PubMedCrossRef
621.
Fortun J, Muriel A, Martin-Davila P, Montejo M, Len O, Torre-Cisneros J, Carratala J, Munoz P, Farinas C, Moreno A, Fresco G, Goikoetxea J, Gavalda J, Pozo JC, Bodro M, Vena A, Casafont F, Cervera C, Silva JT, Aguado JM, Grupo de Estudio de Infeccion en Pacientes Trasplantados-Grupo de Estudio de Micologia M, Red Espanola de Investigacion en Patologia I. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis. Liver Transpl. 2016;22:427–435.
622.
Perrella A, Esposito C, Amato G, Perrella O, Migliaccio C, Pisaniello D, et al. Antifungal prophylaxis with liposomal amphotericin B and caspofungin in high-risk patients after liver transplantation: impact on fungal infections and immune system. Infect Dis (Lond). 2016;48:161–166PubMedCrossRef
623.
Saliba F, Pascher A, Cointault O, Laterre PF, Cervera C, De Waele JJ, Cillo U, Langer RM, Lugano M, Goran-Ericzon B, Phillips S, Tweddle L, Karas A, Brown M, Fischer L, TENPIN Liver Transplant European Study Into the Prevention of Fungal Infection Investigators. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015;60:997–1006.
624.
Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2013;96:573–578PubMedCrossRef
625.
Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K, et al. Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transpl. 2014;14:2758–2764CrossRef
626.
Singh N, Wagener MM, Cacciarelli TV, Levitsky J. Antifungal management practices in liver transplant recipients. Am J Transpl. 2008;8:426–431CrossRef
627.
Vandecasteele E, De Waele J, Vandijck D, Blot S, Vogelaers D, Rogiers X, et al. Antimicrobial prophylaxis in liver transplant patients—a multicenter survey endorsed by the European Liver and Intestine Transplant Association. Transpl Int. 2010;23:182–190PubMedCrossRef
628.
Lavezzo B, Stratta C, Ballaris MA, Tandoi F, Panio A, Donadio PP, Salizzoni M. Invasive Candida infections in low risk liver transplant patients given no antifungal prophylaxis in the post-operative period. Transplant Proc. 2014;46:2312–2313.
629.
Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transpl. 2006;6:386–391CrossRef
630.
San-Juan R, Aguado JM, Lumbreras C, Fortun J, Len O, Munoz P, Montejo M, Moreno A, Cordero E, Blanes M, Ramos A, de la Torre-Cisneros J, Lopez-Medrano F, Carratala J, Moreno E, RESITRA-REIPI Network, Spain. Universal prophylaxis with fluconazole for the prevention of early invasive fungal infection in low-risk liver transplant recipients. Transplantation. 2011;92:346–350.
631.
Trudeau RE, Bowman LJ, Wills AR, Crippin JS, Chapman WC, Anderson C. Once weekly fluconazole for antifungal prophylaxis post-liver transplantation. HPB (Oxford). 2013;15:541–547PubMedCrossRef
632.
Hayes MJ, Torzillo PJ, Sheil AG, McCaughan GW. Pneumocystis carinii pneumonia after liver transplantation in adults. Clin Transpl. 1994;8:499–503
633.
Kostakis ID, Sotiropoulos GC, Kouraklis G. Pneumocystis jirovecii pneumonia in liver transplant recipients: a systematic review. Transpl Proc. 2014;46:3206–3208CrossRef
634.
Fishman JA, Gans H, Practice ASTIDCo. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13587.
635.
Iriart X, Challan Belval T, Fillaux J, Esposito L, Lavergne RA, Cardeau-Desangles I, et al. Risk factors of Pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. Am J Transpl. 2015;15:190–199CrossRef
636.
Min EK, Lee J, Jeong SJ, Kim DG, Yim SH, Choi MC, et al. Risk factors for late-onset Pneumocystis jirovecii pneumonia in liver transplant recipients. Int J Infect Dis. 2023;131:166–172PubMedCrossRef
637.
Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002;8:123–131PubMedCrossRef
638.
Hashim M, Alsebaey A, Ragab A, Soliman HE, Waked I. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: a single center study. Ann Hepatol. 2020;19:541–545PubMedCrossRef
639.
Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B, HIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002;8:132–142.
640.
TruneCka P, Klempnauer J, Bechstein WO, Pirenne J, Friman S, Zhao A, Isoniemi H, Rostaing L, Settmacher U, Monch C, Brown M, Undre N, Tisone G, DIAMOND† study group. Renal function in de novo liver transplant recipients receiving different prolonged-release tacrolimus regimens-the DIAMOND Study. Am J Transpl. 2015;15:1843–1854.
641.
Verna EC, Farrand ED, Elnaggar AS, Pichardo EM, Balducci A, Emond JC, et al. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. Transplantation. 2011;91:1254–1260PubMedCrossRef
642.
Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl. 2008;14:66–72PubMedCrossRef
643.
Benítez CE, Puig-Pey I, López M, Martinez-Llordella M, Lozano JJ, Bohne F, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transpl. 2010;10:2296–2304CrossRef
644.
Iesari S, Ackenine K, Foguenne M, De Reyck C, Komuta M, Bonaccorsi Riani E, et al. Tacrolimus and single intraoperative high-dose of anti-T-lymphocyte globulins versus tacrolimus monotherapy in adult liver transplantation: one-year results of an investigator-driven randomized controlled trial. Ann Surg. 2018;268:776–783PubMedCrossRef
645.
Nair A, Coromina Hernandez L, Shah S, Zervos X, Zimmerman M, Sasaki K, et al. Induction therapy with antithymocyte globulin and delayed calcineurin inhibitor initiation for renal protection in liver transplantation: a multicenter randomized controlled phase II-B trial. Transplantation. 2022;106:997–1003PubMedCrossRef
646.
Soliman T, Hetz H, Burghuber C, Gyori G, Silberhumer G, Steininger R, et al. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int. 2007;20:447–452PubMedCrossRef
647.
Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl. 2011;17(Suppl 3):S1-9PubMedCrossRef
648.
Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, et al. Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study. Ann Surg Treat Res. 2016;90:36–42PubMedCrossRef
649.
Cholongitas E, Shusang V, Germani G, Tsochatzis E, Raimondo ML, Marelli L, et al. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clin Transpl. 2011;25:614–624CrossRef
650.
O'Grady JG, Hardy P, Burroughs AK, Elbourne D, UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transpl. 2007;7:137–141.
651.
McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transpl. 2006;6:1578–1585CrossRef
652.
Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet. 2004;364:1054–1061PubMedCrossRef
653.
Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl. 2003;9:587–595PubMedCrossRef
654.
Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM, Keck H, et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transpl Proc. 1999;31:1113–1114CrossRef
655.
Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA, Kimball PM, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation. 1998;66:1616–1621PubMedCrossRef
656.
U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110–1115.
657.
European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994;344:423–428.
658.
Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transpl Proc. 1991;23:2977–2983
659.
Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10:1258–1262PubMedCrossRef
660.
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G, LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation. 2004;77:1632–1638.
661.
O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet. 2002;360:1119–1125.
662.
Muhlbacher F, European Liver Transplantation Tacrolimus vs Cyclosporin Microemulsion Study Group. Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study. Transpl Proc. 2001;33:1339–1340.
663.
Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation. 1999;68:1195–1198PubMedCrossRef
664.
Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation. 1998;65:1044–1046PubMedCrossRef
665.
Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation. 1997;64:1755–1760PubMedCrossRef
666.
Shin MH, Song GW, Lee SG, Hwang S, Kim KH, Ahn CS, et al. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study. Clin Transpl. 2018;32:e13376CrossRef
667.
Kim JM, Kwon CH, Joh JW, Sinn DH, Lee S, Choi GS, et al. Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: a randomized prospective study. Liver Transpl. 2016;22:209–216PubMedCrossRef
668.
Dumortier J, Guillaud O, Boillot O. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl. 2013;19:529–533PubMedCrossRef
669.
Trunecka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon BG, Troisi RI, Baccarani U, Ortiz de Urbina J, Wall W, Tacrolimus Prolonged Release Liver Study Group. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transpl. 2010;10:2313–2323.
670.
Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity after orthotopic liver transplantation in cyclosporin A and FK 506-treated patients. Transpl Int. 1994;7(Suppl 1):S52-57PubMedCrossRef
671.
Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation. 1994;58:170–178.
672.
Campo A. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:2563–2565; author reply 2563–2565.
673.
de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000;35:333–346PubMedCrossRef
674.
Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O’Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. 2013;59:1193–1199PubMedCrossRef
675.
Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248:857–862PubMedCrossRef
676.
Weber M, Kadry Z, Clavien PA. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation. 2002;74:1664–1665PubMed
677.
Tjon AS, Sint Nicolaas J, Kwekkeboom J, de Man RA, Kazemier G, Tilanus HW, et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl. 2010;16:837–846PubMedCrossRef
678.
Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther. 2001;15:1699–1708PubMedCrossRef
679.
680.
Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. 2001;7:442–450PubMedCrossRef
681.
Fischer L, Sterneck M, Gahlemann CG, Malago M, Rogiers X, Broelsch CE. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. Transpl Proc. 2000;32:2125–2127CrossRef
682.
Sterneck M, Fischer L, Gahlemann C, Gundlach M, Rogiers X, Broelsch C. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial. Ann Transpl. 2000;5:43–46
683.
Castedal M, Skoglund C, Axelson C, Bennet W. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation. Scand J Gastroenterol. 2018;53:741–747PubMedCrossRef
684.
Ramirez CB, Doria C, Frank AM, Armenti ST, Marino IR. Completely steroid-free immunosuppression in liver transplantation: a randomized study. Clin Transpl. 2013;27:463–471CrossRef
685.
Pelletier SJ, Nadig SN, Lee DD, Ammori JB, Englesbe MJ, Sung RS, et al. A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years. HPB (Oxford). 2013;15:286–293PubMedCrossRef
686.
Lerut J, Mathys J, Verbaandert C, Talpe S, Ciccarelli O, Lemaire J, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg. 2008;248:956–967PubMedCrossRef
687.
Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, et al. Tacrolimus monotherapy without steroids after liver transplantation–a prospective randomized double-blinded placebo-controlled trial. Am J Transpl. 2007;7:1616–1623CrossRef
688.
Pageaux GP, Calmus Y, Boillot O, Ducerf C, Vanlemmens C, Boudjema K, Samuel D, French CHI-F-01 Study Group. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl. 2004;10:1454–1460.
689.
Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol. 2012;56:288–290PubMedCrossRef
690.
McKenna GJ, Trotter JF. Sirolimus—it doesn’t deserve its bad Rap(a). J Hepatol. 2012;56:285–287PubMedCrossRef
691.
Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003;9:463–468PubMedCrossRef
692.
McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl. 2001;7:701–708PubMedCrossRef
693.
Biselli M, Vitale G, Gramenzi A, Riili A, Berardi S, Camma C, et al. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transpl. 2009;23:191–198CrossRef
694.
Cicinnati VR, Yu Z, Klein CG, Sotiropoulos GC, Saner F, Malago M, et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients–assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther. 2007;26:1195–1208PubMedCrossRef
695.
Creput C, Blandin F, Deroure B, Roche B, Saliba F, Charpentier B, et al. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation. Liver Transpl. 2007;13:1004–1010PubMedCrossRef
696.
Pageaux GP, Rostaing L, Calmus Y, Duvoux C, Vanlemmens C, Hardgwissen J, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl. 2006;12:1755–1760PubMedCrossRef
697.
Reich DJ, Clavien PA, Hodge EE, MMF Renal Dysfunction after Liver Transplantation Working Group. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. Transplantation. 2005;80:18–25.
698.
Lee SG, Jeng LB, Saliba F, Singh Soin A, Lee WC, De Simone P, et al. Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation. 2021;105:1564–1575PubMedCrossRef
699.
Nashan B, Schemmer P, Braun F, Schlitt HJ, Pascher A, Klein CG, Neumann UP, Kroeger I, Wimmer P, Hephaistos Study Group. Early everolimus-facilitated reduced tacrolimus in liver transplantation: results from the randomized HEPHAISTOS trial. Liver Transpl. 2022;28:998–1010.
700.
Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, Duvoux C, Nevens F, Fung JJ, Dong G, Rauer B, Junge G, H2304 Study Group. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation. 2015;99:1455–1462.
701.
Saliba F, Dharancy S, Salame E, Conti F, Eyraud D, Radenne S, et al. Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER registry. Liver Transpl. 2020;26:1465–1476PubMedCrossRef
702.
Calmus Y, Kamar N, Gugenheim J, Duvoux C, Ducerf C, Wolf P, et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation. 2010;89:1504–1510PubMedCrossRef
703.
Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, Rostaing L, Rimola A, Marshall S, Mayer AD, ReSpECT Study Group. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transpl. 2009;9:327–336.
704.
Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl. 2005;11:1064–1072.
705.
Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation. 2002;74:1746–1751PubMedCrossRef
706.
Yan X, Huang S, Yang Y, Lu Z, Li F, Jiang L, et al. Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Liver Transpl. 2022;28:1063–1077PubMedCrossRef
707.
Kang I, Lee JG, Choi SH, Kim HJ, Han DH, Choi GH, et al. Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma. Clin Mol Hepatol. 2021;27:589–602PubMedPubMedCentralCrossRef
708.
Kim M, Rhu J, Choi GS, Kim JM, Joh JW. Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation. Ann Surg Treat Res. 2021;101:28–36PubMedPubMedCentralCrossRef
709.
Rodríguez-Perálvarez M, Guerrero M, Barrera L, Ferrin G, Álamo JM, Ayllon MD, et al. Impact of early initiated everolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Transplantation. 2018;102:2056–2064PubMedCrossRef
710.
Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:411–419PubMedCrossRef
711.
Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012;18:62–69PubMedCrossRef
712.
Geissler EK, Schnitzbauer AA, Zulke C, Lamby PE, Proneth A, Duvoux C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation. 2016;100:116–125PubMedCrossRef
713.
Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, et al. mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg. 2020;272:855–862PubMedCrossRef
714.
Invernizzi F, Iavarone M, Zavaglia C, Mazza S, Maggi U, Cesarini L, et al. Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation. Transplantation. 2020;104:568–574PubMedCrossRef
715.
Demetris AJ, Todo S, Van Thiel DH, Fung JJ, Iwaki Y, Sysyn G, Ming W, Trager J, Starzl TE. Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol. 1990;137:667–676.
716.
Samuel D, Bismuth A, Mathieu D, Arulnaden JL, Reynes M, Benhamou JP, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet. 1991;337:813–815PubMedCrossRef
717.
Lin LM, Kuo SC, Chiu YC, Lin HF, Kuo ML, Elsarawy AM, et al. Cost analysis and determinants of living donor liver transplantation in Taiwan. Transpl Proc. 2018;50:2601–2605CrossRef
718.
Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl. 2003;3:250–258CrossRef
719.
Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, et al. YMDD motif mutation profile among patients receiving liver transplant due to hepatitis B virus infection with long term lamivudine/immunoglobulin therapy. Hepat Mon. 2015;15:e27120PubMedPubMedCentralCrossRef
720.
Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S, Adefovir Dipivoxil Study 45 Intrnational Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349–360.
721.
Cholongitas E, Goulis I, Antoniadis N, Fouzas I, Imvrios G, Papanikolaou V, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence. Transpl Int. 2014;27:1022–1028PubMedCrossRef
722.
Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir alafenamide for the treatment of chronic hepatitis B monoinfection. Pharmacotherapy. 2018;38:1051–1057PubMedCrossRef
723.
Lai Q, Mennini G, Giovanardi F, Rossi M, Giannini EG. Immunoglobulin, nucleos(t)ide analogues and hepatitis B virus recurrence after liver transplant: a meta-analysis. Eur J Clin Invest. 2021;51:e13575PubMedPubMedCentralCrossRef
724.
Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transpl. 2013;13:353–362CrossRef
725.
Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, et al. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation. JGH Open. 2018;2:288–294PubMedPubMedCentralCrossRef
726.
Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, et al. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018;50:944–953PubMedCrossRef
727.
Fernandez I, Loinaz C, Hernandez O, Abradelo M, Manrique A, Calvo J, et al. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis. 2015;17:695–701PubMedCrossRef
728.
Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, et al. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol. 2013;48:1401–1410PubMedCrossRef
729.
Ku W, Wang U, Nguyen MH. Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation. Expert Opin Biol Ther. 2015;15:665–677PubMedCrossRef
730.
Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–687PubMedCrossRef
731.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–896PubMedCrossRef
732.
Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–684PubMedCrossRef
733.
Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250–256PubMedCrossRef
734.
Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transpl. 2008;8:679–687CrossRef
735.
Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol. 2007;46:459–465PubMedCrossRef
736.
Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–836PubMedCrossRef
737.
Wellington J, Ma A, Kottilil S, Ravichandran B, Husson J, Bruno D, et al. Outcomes in hepatitis C positive liver transplantation: timing of direct-acting antiviral treatment and impact on graft fibrosis. Viruses. 2021;13:1831PubMedPubMedCentralCrossRef
738.
Russo FP, Zanetto A, Burra P. Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. Transpl Int. 2016;29:694–697PubMedCrossRef
739.
Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015;61:1485–1494PubMedCrossRef
740.
Corpechot C, Chazouilleres O, Belnou P, Montano-Loza AJ, Mason A, Ebadi M, Eurich D, Chopra S, Jacob D, Schramm C, Sterneck M, Bruns T, Reuken P, Rauchfuss F, Roccarina D, Thorburn D, Gerussi A, Trivedi P, Hirschfield G, McDowell P, Nevens F, Boillot O, Bosch A, Giostra E, Conti F, Poupon R, Pares A, Reig A, Donato MF, Malinverno F, Floreani A, Russo FP, Cazzagon N, Verhelst X, Goet J, Harms M, van Buuren H, Hansen B, Carrat F, Dumortier J, Global PBC Study Group. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. J Hepatol. 2020;73:559–565.
741.
Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, Hirschfield G, McDowell P, Poupon R, Dumortier J, Bosch A, Giostria E, Conti F, Pares A, Reig A, Floreani A, Russo FP, Goet JC, Harms MH, van Buuren H, Van den Ende N, Nevens F, Verhelst X, Donato MF, Malinverno F, Ebadi M, Mason AL, Global PBC Study Group. Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival. Gastroenterology. 2019;156:96–107.e1.
742.
Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation. Am J Transpl. 2010;10:852–858CrossRef
743.
Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004;10:488–491PubMedCrossRef
744.
Bosch A, Dumortier J, Maucort-Boulch D, Scoazec JY, Wendum D, Conti F, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol. 2015;63:1449–1458PubMedCrossRef
745.
Pedersen MR, Greenan G, Arora S, Murali AR, Mayo MJ. Ursodeoxycholic acid decreases incidence of primary biliary cholangitis and biliary complications after liver transplantation: a meta-analysis. Liver Transpl. 2021;27:866–875PubMedCrossRef
746.
747.
748.
Ravikumar R, Tsochatzis E, Jose S, Allison M, Athale A, Creamer F, et al. Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. J Hepatol. 2015;63:1139–1146PubMedCrossRef
749.
Alabraba E, Nightingale P, Gunson B, Hubscher S, Olliff S, Mirza D, et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl. 2009;15:330–340PubMedCrossRef
750.
Dvorchik I, Subotin M, Demetris AJ, Fung JJ, Starzl TE, Wieand S, et al. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology. 2002;35:380–384PubMedCrossRef
751.
Jorgensen KK, Lindstrom L, Cvancarova M, Karlsen TH, Castedal M, Friman S, et al. Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:517–523PubMedCrossRef
752.
Futagawa Y, Terasaki PI. An analysis of the OPTN/UNOS liver transplant registry. Clin Transpl 2004;315-29
753.
Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671–722PubMedCrossRef
754.
Jain A, Kashyap R, Marsh W, Rohal S, Khanna A, Fung JJ. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation. 2001;71:1102–1106PubMedCrossRef
755.
Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl. 2009;15:1254–1261PubMedCrossRef
756.
Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006;12:1813–1824PubMedCrossRef
757.
Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68:253–256PubMedCrossRef
758.
Ratziu V, Samuel D, Sebagh M, Farges O, Saliba F, Ichai P, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol. 1999;30:131–141PubMedCrossRef
759.
Montano-Loza AJ, Ronca V, Ebadi M, Hansen BE, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik MK, Marschall HU, Burza MA, Efe C, Caliskan AR, Harputluoglu M, Kabacam G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Pares A, Llovet L, Akyildiz M, Arikan C, Manns MP, Taubert R, Weber AL, Schiano TD, Haydel B, Czubkowski P, Socha P, Oldak N, Akamatsu N, Tanaka A, Levy C, Martin EF, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato MF, Lohse A, Andrade RJ, Patwardhan VR, van Hoek B, Biewenga M, Kremer AE, Ueda Y, Deneau M, Pedersen M, Mayo MJ, Floreani A, Burra P, Secchi MF, Beretta-Piccoli BT, Sciveres M, Maggiore G, Jafri SM, Debray D, Girard M, Lacaille F, Lytvyak E, Mason AL, Heneghan M, Oo YH, International Autoimmune Hepatitis Group (IAIHG). Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. J Hepatol. 2022;77:84–97.
760.
Krishnamoorthy TL, Miezynska-Kurtycz J, Hodson J, Gunson BK, Neuberger J, Milkiewicz P, et al. Longterm corticosteroid use after liver transplantation for autoimmune hepatitis is safe and associated with a lower incidence of recurrent disease. Liver Transpl. 2016;22:34–41PubMedCrossRef
761.
Demetris AJ, Sebagh M. Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis? Liver Transpl. 2008;14:750–755PubMedCrossRef
762.
Stirnimann G, Ebadi M, Czaja AJ, Montano-Loza AJ. Recurrent and de novo autoimmune hepatitis. Liver Transpl. 2019;25:152–166PubMedCrossRef
763.
Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther. 2017;45:485–500PubMedCrossRef
764.
Kwon JH, Hanouneh IA, Allende D, Yerian L, Diago T, Eghtesad B, et al. De novo autoimmune hepatitis following liver transplantation. Transpl Proc. 2018;50:1451–1456CrossRef
765.
Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis. 2011;15:859–878PubMedCrossRef
766.
Young TA, Neuberger J, Longworth L, Ratcliffe J, Buxton MJ, Cost-Effectiveness in Liver Transplantation Study Team. Survival gain after liver transplantation for patients with alcoholic liver disease: a comparison across models and centers. Transplantation. 2003;76:1479–1486.
767.
Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation. 2001;72:619–626PubMedPubMedCentralCrossRef
768.
Lee BP, Vittinghoff E, Dodge JL, Cullaro G, Terrault NA. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med. 2019;179:340–348PubMedPubMedCentralCrossRef
769.
770.
Rice JP, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013;19:1377–1386PubMedCrossRef
771.
Cuadrado A, Fabrega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2005;11:420–426PubMedCrossRef
772.
Bjornsson E, Olsson J, Rydell A, Fredriksson K, Eriksson C, Sjoberg C, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol. 2005;40:206–216PubMedCrossRef
773.
Bathgate AJ, Liver UK. Transplant units’ working party. Recommendations for alcohol-related liver disease. Lancet. 2006;367:2045–2046PubMedCrossRef
774.
Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:394-402.e1PubMedCrossRef
775.
Cotter TG, Charlton M. Nonalcoholic steatohepatitis after liver transplantation. Liver Transpl. 2020;26:141–159PubMedCrossRef
776.
Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005;18:461–466PubMedCrossRef
777.
Krasnoff JB, Vintro AQ, Ascher NL, Bass NM, Paul SM, Dodd MJ, et al. A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transpl. 2006;6:1896–1905CrossRef
778.
Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg. 1998;4:285–296PubMedCrossRef
779.
Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg. 1997;3:1–9PubMedCrossRef
780.
Nakamuta M, Morizono S, Soejima Y, Yoshizumi T, Aishima S, Takasugi S, et al. Short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Transplantation. 2005;80:608–612PubMedCrossRef
781.
Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg. 2017;266:118–125PubMedCrossRef
782.
de'Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol. 2015;21:11185–11198.
783.
Nagai S, Mangus RS, Kubal CA, Ekser B, Fridell JA, Klingler KR, et al. Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival. Clin Transpl. 2015;29:1156–1163CrossRef
784.
Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol. 2015;22:2286–2294PubMedCrossRef
785.
Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation. World J Hepatol. 2019;11:261–272PubMedPubMedCentralCrossRef
786.
Xu M, Doyle MM, Banan B, Vachharajani N, Wang X, Saad N, et al. Neoadjuvant locoregional therapy and recurrent hepatocellular carcinoma after liver transplantation. J Am Coll Surg. 2017;225:28–40PubMedPubMedCentralCrossRef
787.
Guerrini GP, Berretta M, Tarantino G, Magistri P, Pecchi A, Ballarin R, et al. Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation. Eur Rev Med Pharmacol Sci. 2017;21:3421–3435PubMed
788.
Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, et al. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019;21:731–738PubMedCrossRef
789.
Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: a proposed management algorithm. World J Gastroenterol. 2018;24:5081–5094PubMedPubMedCentralCrossRef
790.
Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, et al. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol. 2010;17:2283–2289PubMedCrossRef
791.
Sanner T. Formation of transient complexes in the glutamate dehydrogenase catalyzed reaction. Biochemistry. 1975;14:5094–5098PubMedCrossRef
792.
Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, Fernandez JR, Pijoan I, Testillano M, Suarez MJ, Montejo M, Ortiz de Urbina J. Management of hepatocellular carcinoma recurrence after liver transplantation. Transpl Proc. 2010;42:660–662.
793.
Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol. 2010;21:333–338PubMedCrossRef
794.
Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, Marsh C, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol. 2006;12:5729–5732PubMedPubMedCentralCrossRef
795.
Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case–control study. J Hepatol. 2013;59:59–66PubMedCrossRef
796.
Iavarone M, Invernizzi F, Ivanics T, Mazza S, Zavaglia C, Sanduzzi-Zamparelli M, et al. Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study. Liver Transpl. 2021;27:1767–1778PubMedCrossRef
797.
Biondani P, De Martin E, Samuel D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol. 2018;29:286–287PubMedCrossRef
798.
Corman SL, Coley KC, Schonder KS. Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients. Pharmacotherapy. 2006;26:1433–1437PubMedCrossRef
799.
Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–940PubMedCrossRef
800.
Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934–1939PubMedCrossRef
801.
Gonwa TA, McBride MA, Mai ML, Wadei HM. Kidney transplantation after previous liver transplantation: analysis of the organ procurement transplant network database. Transplantation. 2011;92:31–35PubMedCrossRef
802.
Wagner D, Kniepeiss D, Stiegler P, Zitta S, Bradatsch A, Robatscher M, et al. The assessment of GFR after orthotopic liver transplantation using cystatin C and creatinine-based equations. Transpl Int. 2012;25:527–536PubMedCrossRef
803.
Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26PubMedCrossRef
804.
Saner FH, Cicinnati VR, Sotiropoulos G, Beckebaum S. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation. Liver Int. 2012;32:179–188PubMedCrossRef
805.
Klintmalm GB, Gonwa TA. Nephrotoxicity associated with cyclosporine and FK506. Liver Transpl Surg. 1995;1:11–19PubMed
806.
Pelaez-Jaramillo MJ, Cardenas-Mojica AA, Gaete PV, Mendivil CO. Post-liver transplantation diabetes mellitus: a review of relevance and approach to treatment. Diabetes Ther. 2018;9:521–543PubMedPubMedCentralCrossRef
807.
Trail KC, McCashland TM, Larsen JL, Heffron TG, Stratta RJ, Langnas AN, et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg. 1996;2:276–283PubMedCrossRef
808.
Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, et al. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther. 2014;40:686–694PubMedCrossRef
809.
Shivaswamy V, Boerner B, Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr Rev. 2016;37:37–61PubMedCrossRef
810.
Sadhu AR, Schwartz SS, Herman ME. The rationale for use of incretins in the management of new onset diabetes after transplantation (Nodat). Endocr Pract. 2015;21:814–822PubMedCrossRef
811.
Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation. 1995;60:1057–1060.
812.
Textor SC, Canzanello VJ, Taler SJ, Schwartz L, Augustine J. Hypertension after liver transplantation. Liver Transpl Surg. 1995;1:20–28PubMed
813.
Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transpl. 2004;18:94–99CrossRef
814.
Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585CrossRef
815.
Galioto A, Semplicini A, Zanus G, Fasolato S, Sticca A, Boccagni P, et al. Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. Liver Transpl. 2008;14:1020–1028PubMedCrossRef
816.
Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol. 2010;53:199–206PubMedCrossRef
817.
Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben AZ. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011;17:15–22PubMedCrossRef
818.
Haagsma EB, Thijn CJ, Post JG, Slooff MJ, Gips CH. Bone disease after orthotopic liver transplantation. J Hepatol. 1988;6:94–100PubMedCrossRef
819.
Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 2006;12:1390–1402PubMedCrossRef
820.
Guichelaar MM, Schmoll J, Malinchoc M, Hay JE. Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology. 2007;46:1198–1207PubMedCrossRef
821.
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33:2049–2102PubMedPubMedCentralCrossRef
822.
Stein EM, Ortiz D, Jin Z, McMahon DJ, Shane E. Prevention of fractures after solid organ transplantation: a meta-analysis. J Clin Endocrinol Metab. 2011;96:3457–3465PubMedPubMedCentralCrossRef
823.
Isoniemi H, Appelberg J, Nilsson CG, Makela P, Risteli J, Hockerstedt K. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol. 2001;34:299–305.
824.
Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005;90:3877–3885PubMedCrossRef
825.
Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transpl. 2016;16:1882–1891CrossRef
826.
Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation. 2006;81:686–691PubMedCrossRef
827.
Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int. 2001;12:112–116PubMedCrossRef
828.
Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int. 2003;14:82–89PubMedCrossRef
829.
Ippoliti G, Pellegrini C, Campana C, Rinaldi M, D’Armini A, Goggi C, et al. Clodronate treatment of established bone loss in cardiac recipients: a randomized study. Transplantation. 2003;75:330–334PubMedCrossRef
830.
Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol (Lausanne). 2018;9:162PubMedCrossRef
831.
Aberg F, Gissler M, Karlsen TH, Ericzon BG, Foss A, Rasmussen A, et al. Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study. Hepatology. 2015;61:668–677PubMedCrossRef
832.
Patel JA, Daoud D, Jain A. Review of Standardized Incidence Ratios (SIR) of non-lymphoid de novo malignancies after liver transplantation: Structured analysis of global differences. Transpl Rev (Orlando). 2022;36:100670CrossRef
833.
Colmenero J, Tabrizian P, Bhangui P, Pinato DJ, Rodriguez-Peralvarez ML, Sapisochin G, et al. De novo malignancy after liver transplantation: risk assessment, prevention, and management-guidelines from the ILTS-SETH consensus conference. Transplantation. 2022;106:e30–e45PubMedCrossRef
834.
Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, et al. De novo malignancies after liver transplantation: incidence comparison with the Korean cancer registry. Transpl Proc. 2012;44:802–805CrossRef
835.
Gong CS, Yoo MW, Kim BS, Hwang S, Kim KH, Yook JH, et al. De novo gastric cancer after liver transplantation. Ann Transpl. 2016;21:386–391CrossRef
836.
Kim S, Rovgaliyev B, Lee JM, Lee KW, Hong SK, Cho JH, et al. Clinical significance of de novo malignancy after liver transplant: a single-center study. Transpl Proc. 2021;53:200–206CrossRef
837.
Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation between immune-related adverse events and prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors. Front Immunol. 2021;12:794099PubMedPubMedCentralCrossRef
838.
Nure E, Frongillo F, Lirosi MC, Grossi U, Sganga G, Avolio AW, et al. Incidence of upper aerodigestive tract cancer after liver transplantation for alcoholic cirrhosis: a 10-year experience in an Italian center. Transpl Proc. 2013;45:2733–2735CrossRef
839.
Seree O, Altieri M, Guillaume E, De Mil R, Lobbedez T, Robinson P, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a french national study on 11,226 patients. Liver Transpl. 2018;24:1425–1436PubMedCrossRef
840.
Nasser-Ghodsi N, Mara K, Watt KD. De novo colorectal and pancreatic cancer in liver-transplant recipients: identifying the higher-risk populations. Hepatology. 2021;74:1003–1013PubMedCrossRef
841.
Renaud L, Hilleret MN, Thimonier E, Guillaud O, Arbib F, Ferretti G, et al. De novo malignancies screening after liver transplantation for alcoholic liver disease: a comparative opportunistic study. Liver Transpl. 2018;24:1690–1698PubMedCrossRef
842.
Di Credico G, Polesel J, Dal Maso L, Pauli F, Torelli N, Luce D, Radoi L, Matsuo K, Serraino D, Brennan P, Holcatova I, Ahrens W, Lagiou P, Canova C, Richiardi L, Healy CM, Kjaerheim K, Conway DI, Macfarlane GJ, Thomson P, Agudo A, Znaor A, Franceschi S, Herrero R, Toporcov TN, Moyses RA, Muscat J, Negri E, Vilensky M, Fernandez L, Curado MP, Menezes A, Daudt AW, Koifman R, Wunsch-Filho V, Olshan AF, Zevallos JP, Sturgis EM, Li G, Levi F, Zhang ZF, Morgenstern H, Smith E, Lazarus P, La Vecchia C, Garavello W, Chen C, Schwartz SM, Zheng T, Vaughan TL, Kelsey K, McClean M, Benhamou S, Hayes RB, Purdue MP, Gillison M, Schantz S, Yu GP, Chuang SC, Boffetta P, Hashibe M, Yuan-Chin AL, Edefonti V. Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. Br J Cancer. 2020;123:1456–1463.
843.
Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Engl J Med. 2018;378:549–562PubMedCrossRef
844.
Gwon JG, Kim YH, Han DJ. Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000. Asian J Surg. 2019;42:551–556PubMedCrossRef
845.
Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088PubMedCrossRef
846.
Okamoto T, Okajima H, Uebayashi EY, Ogawa E, Yamada Y, Umeda K, et al. Management of epstein-barr virus infection and post-transplant lymphoproliferative disorder in pediatric liver transplantation. J Clin Med. 2022;11:2166PubMedPubMedCentralCrossRef
847.
Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transpl. 2019;33:e13652.
848.
Charlton M, Levitsky J, Aqel B, O’Grady J, Hemibach J, Rinella M, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727–743PubMedCrossRef
849.
Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer. 2019;144:886–896PubMedCrossRef
850.
DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018;9:1054–1062PubMedPubMedCentralCrossRef
851.
Subramanian AK, Morris MI, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transpl. 2013;13 Suppl 4:68–76.
852.
Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009;15:894–906PubMedCrossRef
853.
Aguado JM, Torre-Cisneros J, Fortun J, Benito N, Meije Y, Doblas A, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48:1276–1284PubMedCrossRef
854.
Leong LY, Lin PC, Chi CY, Chou CH, Lu MC, Liao WC, et al. Risk factors of tuberculosis after liver transplant in a tertiary care hospital. J Microbiol Immunol Infect. 2021;54:312–318PubMedCrossRef
855.
Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27:1266–1277PubMedCrossRef
856.
Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40:581–587PubMedCrossRef
857.
Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, Moreno A, Gurgui M, Hayek M, Lumbreras C, Cantarell C. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63:1278–1286.
858.
Lattes R, Radisic M, Rial M, Argento J, Casadei D. Tuberculosis in renal transplant recipients. Transpl Infect Dis. 1999;1:98–104PubMedCrossRef
859.
Keating MR, Daly JS, AST Infectious Diseases Community of Practice. Nontuberculous mycobacterial infections in solid organ transplantation. Am J Transpl. 2013;13 Suppl 4:77–82.
860.
Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis. 1994;19:263–273PubMedCrossRef
861.
Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38:1428–1439PubMedCrossRef
862.
Longworth SA, Vinnard C, Lee I, Sims KD, Barton TD, Blumberg EA. Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case–control study. Transpl Infect Dis. 2014;16:76–83PubMedCrossRef
863.
Campos-Varela I, Dodge JL, Terrault NA, Brandman D, Price JC. Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus. Am J Transpl. 2021;21:3148–3156CrossRef
864.
Werbel WA, Durand CM. Clearing the hepatitis hurdle: obstacles and opportunities in liver transplantation for people with HIV. Am J Transpl. 2021;21:2931–2932CrossRef
865.
Shetty A, Kodali S. Long-term management of the successful adult liver transplant: a patient-friendly summary of the 2012 AASLD and AST practice guideline. Clin Liver Dis (Hoboken). 2022;19:83–88PubMedCrossRef
866.
Fox AN, Vagefi PA, Stock PG. Liver transplantation in HIV patients. Semin Liver Dis. 2012;32:177–185PubMedCrossRef
867.
868.
Blumberg EA, Rogers CC, American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13499.
869.
Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239–247PubMedCrossRef
870.
Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003;188:1412–1420PubMedCrossRef
871.
Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transpl. 2008;8:355–365CrossRef
872.
Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl. 2004;10:1271–1278PubMedCrossRef
873.
Blumberg EA, Stock P, AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient. Am J Transpl. 2009;9 Suppl 4:S131–135.
874.
Kardashian AA, Price JC. Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transpl. 2015;20:276–285CrossRef
875.
Antonini TM, Sebagh M, Roque-Afonso AM, Teicher E, Roche B, Sobesky R, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transpl. 2011;11:1686–1695CrossRef
876.
Marciano S, Galdame OA, Barcan LA, Gadano AC. Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient. Acta Gastroenterol Latinoam. 2015;45:76–79PubMed
877.
Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, Botta D, Durand F, Silvain C, Lebray P, Houssel-Debry P, Kamar N, D'Alteroche L, Petrov-Sanchez V, Diallo A, Pageaux GP, Duclos-Vallee JC, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO23 compassionate use of protease inhibitors in viral C in liver transplantation study group. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol. 2015;13:1993–2001.e1–2.
878.
Saab S, Jimenez M, Bau S, Goo T, Zhao D, Durazo F, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. Clin Transpl. 2015;29:813–819CrossRef
879.
Grant JL, Hawkins C, Brooks H, Palella FJ Jr, Koppe SW, Abecassis MM, et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS. 2016;30:93–98PubMedCrossRef
880.
D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26:832–834PubMedCrossRef
881.
Colmenero J, Rodríguez-Perálvarez M, Salcedo M, Arias-Milla A, Munoz-Serrano A, Graus J, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74:148–155PubMedCrossRef
882.
Mohammed A, Paranji N, Chen PH, Niu B. COVID-19 in chronic liver disease and liver transplantation: a clinical review. J Clin Gastroenterol. 2021;55:187–194PubMedCrossRef
883.
Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, Armstrong D, Yurdaydin C. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021;55:1–11.
884.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720.
885.
Liu H, He X, Wang Y, Zhou S, Zhang D, Zhu J, et al. Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation. Hepatol Int. 2020;14:432–436PubMedCrossRef
886.
Mansoor E, Perez A, Abou-Saleh M, Sclair SN, Cohen S, Cooper GS, et al. Clinical characteristics, hospitalization, and mortality rates of coronavirus disease 2019 among liver transplant patients in the United States: a multicenter research network study. Gastroenterology. 2021;160:459-462.e1PubMedCrossRef
887.
888.
889.
Solera JT, Arbol BG, Bahinskaya I, Marks N, Humar A, Kumar D. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave. Am J Transpl. 2023;23:78–83.
890.
Cacho J, Nicolas D, Bodro M, Cuadrado-Payan E, Torres-Jaramillo V, Gonzalez-Rojas A, et al. Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection. Kidney Int. 2022;102:917–921PubMedPubMedCentralCrossRef
891.
Elec F, Magnusson J, Elec A, Muntean A, Antal O, Moisoiu T, et al. COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome—a retrospective cohort study. Int J Infect Dis. 2022;118:247–253PubMedPubMedCentralCrossRef
892.
Sait AS, Chiang TP, Marr KA, Massie AB, Cochran W, Shah P, et al. Outcomes of SOT recipients with COVID-19 in different eras of COVID-19 therapeutics. Transpl Direct. 2022;8:e1268CrossRef
893.
Fishbane S, Hirsch JS, Nair V. Special considerations for paxlovid treatment among transplant recipients with SARS-CoV-2 infection. Am J Kidney Dis. 2022;79:480–482PubMedPubMedCentralCrossRef
894.
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2:100113PubMedPubMedCentralCrossRef
895.
Gangappa S, Kokko KE, Carlson LM, Gourley T, Newell KA, Pearson TC, et al. Immune responsiveness and protective immunity after transplantation. Transpl Int. 2008;21:293–303PubMedCrossRef
896.
Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Buhler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation—a systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;35:1216–1226PubMedCrossRef
897.
Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I, Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100.
898.
Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, Campins Marti M, Perez R, Gonzalez Roncero FM, Kumar D, Chiang YJ, Doucette K, Pipeleers L, Aguera Morales ML, Rodriguez-Ferrero ML, Secchi A, McNeil SA, Campora L, Di Paolo E, El Idrissi M, Lopez-Fauqued M, Salaun B, Heineman TC, Oostvogels L, Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020;70:181–190.
899.
L’Huillier AG, Hirzel C, Ferreira VH, Ierullo M, Ku T, Selzner N, et al. Evaluation of recombinant herpes zoster vaccine for primary immunization of varicella-seronegative transplant recipients. Transplantation. 2021;105:2316–2323PubMedCrossRef
900.
Sullivan KM, Farraye FA, Winthrop KL, Willer DO, Vink P, Tavares-Da-Silva F. Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions. Vaccine. 2023;41:36–48PubMedCrossRef
901.
Pittet LF, Verolet CM, McLin VA, Wildhaber BE, Rodriguez M, Cherpillod P, et al. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transpl. 2019;19:844–854CrossRef
902.
Rosenthal A, Madigan T, Chen SF, Gans H, Nadimpalli S. Live virus vaccination of pediatric solid organ transplant candidates within 1 month prior to transplantation: a multicenter experience. Transpl Infect Dis. 2021;23:e13667PubMedCrossRef
903.
Newman AM, Posch LC, Gianchetti L, Rand EB, Mohammad S, Downes KJ, et al. Live virus vaccination following pediatric liver transplantation: outcomes from two academic children’s hospitals. Am J Transpl. 2022;22:1201–1212CrossRef
904.
von Reyn CF. Correcting the record on BCG before we license new vaccines against tuberculosis. J R Soc Med. 2017;110:428–433CrossRef
905.
Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, et al. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl. 2012;18:803–810PubMedPubMedCentralCrossRef
906.
Zhenglu W, Hui L, Shuying Z, Wenjuan C, Zhongyang S. A clinical-pathological analysis of drug-induced hepatic injury after liver transplantation. Transpl Proc. 2007;39:3287–3291CrossRef
907.
Jimenez-Perez M, Gonzalez-Grande R, Garcia-Cortes M, Andrade RJ. Drug-induced liver injury after liver transplantation. Liver Transpl. 2020;26:1167–1176PubMedCrossRef
908.
Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther. 1998;80:1–34PubMedCrossRef
909.
Dopazo C, Bilbao I, Lazaro JL, Sapisochin G, Caralt M, Blanco L, et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transpl Proc. 2009;41:1021–1024CrossRef
910.
Tischer S, Fontana RJ. Drug–drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60:872–884PubMedCrossRef
911.
Tseng A, Foisy M. Important drug–drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep. 2012;14:67–82PubMedCrossRef
912.
Rahim MN, Long L, Penna L, Williamson C, Kametas NA, Nicolaides KH, et al. Pregnancy in liver transplantation. Liver Transpl. 2020;26:564–581PubMedCrossRef
913.
Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation. 1996;62:476–479PubMedCrossRef
914.
Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, Gulati R, McGrory CH, Coscia LA. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2005:69–83.
915.
Jabiry-Zieniewicz Z, Kaminski P, Bobrowska K, Pietrzak B, Wielgos M, Smoter P, et al. Menstrual function in female liver transplant recipients of reproductive age. Transpl Proc. 2009;41:1735–1739CrossRef
916.
Nicholas SL, Rulin MC. Acute vaginal bleeding in women undergoing liver transplantation. Am J Obstet Gynecol. 1994;170:733–736PubMedCrossRef
917.
Sorrell JH, Brown JR. Sexual functioning in patients with end-stage liver disease before and after transplantation. Liver Transpl. 2006;12:1473–1477PubMedCrossRef
918.
Burra P, Germani G, Masier A, De Martin E, Gambato M, Salonia A, et al. Sexual dysfunction in chronic liver disease: is liver transplantation an effective cure? Transplantation. 2010;89:1425–1429PubMedCrossRef
919.
Coscia LA, Constantinescu S, Moritz MJ, Frank A, Ramirez CB, Maley WL, Doria C, McGrory CH, Armenti VT. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2009:103–122.
920.
Christopher V, Al-Chalabi T, Richardson PD, Muiesan P, Rela M, Heaton ND, et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl. 2006;12:1138–1143PubMedCrossRef
921.
Heneghan MA, Selzner M, Yoshida EM, Mullhaupt B. Pregnancy and sexual function in liver transplantation. J Hepatol. 2008;49:507–519PubMedCrossRef
922.
Coffin CS, Shaheen AA, Burak KW, Myers RP. Pregnancy outcomes among liver transplant recipients in the United States: a nationwide case–control analysis. Liver Transpl. 2010;16:56–63PubMedCrossRef
923.
Ghazali S, Czuzoj-Shulman N, Spence AR, Mishkin DS, Abenhaim HA. Pregnancy outcomes in liver transplant patients, a population-based study. J Matern Fetal Neonatal Med. 2017;30:261–266PubMedCrossRef
924.
Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Cameron AM, et al. Pregnancy outcomes of liver transplant recipients: a systematic review and meta-analysis. Liver Transpl. 2012;18:621–629PubMedCrossRef
925.
Blume C, Sensoy A, Gross MM, Guenter HH, Haller H, Manns MP, et al. A comparison of the outcome of pregnancies after liver and kidney transplantation. Transplantation. 2013;95:222–227PubMedCrossRef
926.
Baskiran A, Karakas S, Ince V, Kement M, Ozdemir F, Ozsay O, et al. Pregnancy after liver transplantation: risks and outcomes. Transpl Proc. 2017;49:1875–1878CrossRef
927.
Lim TY, Gonsalkorala E, Cannon MD, Gabeta S, Penna L, Heaton ND, et al. Successful pregnancy outcomes following liver transplantation is predicted by renal function. Liver Transpl. 2018;24:606–615PubMedCrossRef
928.
Nagy S, Bush MC, Berkowitz R, Fishbein TM, Gomez-Lobo V. Pregnancy outcome in liver transplant recipients. Obstet Gynecol. 2003;102:121–128PubMed
929.
Armenti VT, Daller JA, Constantinescu S, Silva P, Radomski JS, Moritz MJ, Gaughan WJ, McGrory CH, Coscia LA. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clin Transpl. 2006:57–70.
930.
Jain AB, Reyes J, Marcos A, Mazariegos G, Eghtesad B, Fontes PA, et al. Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years. Transplantation. 2003;76:827–832PubMedPubMedCentralCrossRef
931.
Westbrook RH, Yeoman AD, Agarwal K, Aluvihare V, O’Grady J, Heaton N, et al. Outcomes of pregnancy following liver transplantation: The King’s College Hospital experience. Liver Transpl. 2015;21:1153–1159PubMedCrossRef
932.
Songin T, Pietrzak B, Brawura-Biskupski-Samaha R, Kociszewska-Najman B, Jabiry-Zieniewicz Z, Cyganek A, et al. Pregnancy after kidney and liver transplantation: its outcome and effect on the graft, mother, and neonate. Ann Transpl. 2014;19:660–666CrossRef
933.
Sibanda N, Briggs JD, Davison JM, Johnson RJ, Rudge CJ. Pregnancy after organ transplantation: a report from the UK transplant pregnancy registry. Transplantation. 2007;83:1301–1307PubMedCrossRef
934.
Alvaro E, Jimenez LC, Palomo I, Manrique A, Alegre C, Garcia M, et al. Pregnancy and orthotopic liver transplantation. Transpl Proc. 2013;45:1966–1968CrossRef
935.
Jabiry-Zieniewicz Z, Szpotanska-Sikorska M, Pietrzak B, Kociszewska-Najman B, Foroncewicz B, Mucha K, et al. Pregnancy outcomes among female recipients after liver transplantation: further experience. Transpl Proc. 2011;43:3043–3047CrossRef
936.
Cyganek A, Pietrzak B, Kociszewska-Najman B, Grzechocinska B, Songin T, Foroncewicz B, et al. Intrauterine growth restriction in pregnant renal and liver transplant recipients: risk factors assessment. Transpl Proc. 2014;46:2794–2797CrossRef
937.
Concepcion BP, Schaefer HM. Caring for the pregnant kidney transplant recipient. Clin Transpl. 2011;25:821–829CrossRef
938.
Ross DS, Dollard SC, Victor M, Sumartojo E, Cannon MJ. The epidemiology and prevention of congenital cytomegalovirus infection and disease: activities of the Centers for Disease Control and Prevention Workgroup. J Womens Health (Larchmt). 2006;15:224–229PubMedCrossRef
939.
Kubo S, Uemoto S, Furukawa H, Umeshita K, Tachibana D, Japanese Liver Transplantation Society. Pregnancy outcomes after living donor liver transplantation: results from a Japanese survey. Liver Transpl. 2014;20:576–583.
940.
Gotestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810PubMedCrossRef
941.
Parhar KS, Gibson PS, Coffin CS. Pregnancy following liver transplantation: review of outcomes and recommendations for management. Can J Gastroenterol. 2012;26:621–626PubMedPubMedCentralCrossRef
942.
Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–1702PubMedCrossRef
943.
Pérgola PE, Kancharla A, Riley DJ. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation. 2001;71:994–997PubMedCrossRef
944.
945.
Skuladottir H, Wilcox AJ, Ma C, Lammer EJ, Rasmussen SA, Werler MM, et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol. 2014;100:499–506PubMedPubMedCentralCrossRef
946.
Bloom SL, Sheffield JS, McIntire DD, Leveno KJ. Antenatal dexamethasone and decreased birth weight. Obstet Gynecol. 2001;97:485–490PubMed
947.
McKinlay CJ, Crowther CA, Middleton P, Harding JE. Repeat antenatal glucocorticoids for women at risk of preterm birth: a Cochrane Systematic Review. Am J Obstet Gynecol. 2012;206:187–194PubMedCrossRef
948.
Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64:559–565PubMedPubMedCentralCrossRef
949.
Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13(Suppl 1):S299-300PubMedCrossRef
950.
McKay DB, Josephson MA, Armenti VT, August P, Coscia LA, Davis CL, Davison JM, Easterling T, Friedman JE, Hou S, Karlix J, Lake KD, Lindheimer M, Matas AJ, Moritz MJ, Riely CA, Ross LF, Scott JR, Wagoner LE, Wrenshall L, Adams PL, Bumgardner GL, Fine RN, Goral S, Krams SM, Martinez OM, Tolkoff-Rubin N, Pavlakis M, Scantlebury V, Women's Health Committee of the American Society of Transplantation. Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transpl. 2005;5:1592–1599.
951.
American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–789CrossRef
952.
Nickels M, Jain A, Sharma R, Orloff M, Tsoulfas G, Kashyap R, et al. Polysubstance abuse in liver transplant patients and its impact on survival outcome. Exp Clin Transpl. 2007;5:680–685
953.
Klimkiewicz A, Klimkiewicz J, Jakubczyk A, Kieres-Salomonski I. Wojnar M [Comorbidity of alcohol dependence with other psychiatric disorders. Part I. Epidemiology of dual diagnosis]. Psychiatr Pol. 2015;49:265–275PubMedCrossRef
954.
Gitto S, Golfieri L, Caputo F, Grandi S, Andreone P. Multidisciplinary view of alcohol use disorder: from a psychiatric illness to a major liver disease. Biomolecules. 2016;6:11PubMedPubMedCentralCrossRef
955.
Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR, HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007;46:420–431.
956.
O’Carroll RE, Couston M, Cossar J, Masterton G, Hayes PC. Psychological outcome and quality of life following liver transplantation: a prospective, national, single-center study. Liver Transpl. 2003;9:712–720PubMedCrossRef
957.
Corruble E, Barry C, Varescon I, Durrbach A, Samuel D, Lang P, et al. Report of depressive symptoms on waiting list and mortality after liver and kidney transplantation: a prospective cohort study. BMC Psychiatry. 2011;11:182PubMedPubMedCentralCrossRef
958.
Rogal SS, Landsittel D, Surman O, Chung RT, Rutherford A. Pretransplant depression, antidepressant use, and outcomes of orthotopic liver transplantation. Liver Transpl. 2011;17:251–260PubMedPubMedCentralCrossRef
959.
Pérez-San-Gregorio MA, Martín-Rodríguez A, Borda-Mas M, Avargues-Navarro ML, Pérez-Bernal J, Gómez-Bravo MA. Coping strategies in liver transplant recipients and caregivers according to patient posttraumatic growth. Front Psychol. 2017;8:18PubMedPubMedCentralCrossRef
960.
Rogal SS, Dew MA, Fontes P, DiMartini AF. Early treatment of depressive symptoms and long-term survival after liver transplantation. Am J Transpl. 2013;13:928–935CrossRef
961.
Golfieri L, Lauro A, Tossani E, Sirri L, Dazzi A, Zanfi C, et al. Coping strategies in intestinal transplantation. Transpl Proc. 2007;39:1992–1994CrossRef
962.
Telles-Correia D, Barbosa A, Mega I, Barroso E, Monteiro E. Psychiatric and psychosocial predictors of medical outcome after liver transplantation: a prospective, single-center study. Transpl Proc. 2011;43:155–157CrossRef
Metadata
Title
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation
Authors
Dong-Sik Kim
Young-In Yoon
Beom Kyung Kim
Ashok Choudhury
Anand Kulkarni
Jun Yong Park
Jongman Kim
Dong Hyun Sinn
Dong Jin Joo
YoungRok Choi
Jeong-Hoon Lee
Ho Joong Choi
Ki Tae Yoon
Sun Young Yim
Cheon-Soo Park
Deok-Gie Kim
Hae Won Lee
Won-Mook Choi
Young Eun Chon
Woo-Hyoung Kang
Jinsoo Rhu
Jae Geun Lee
Yuri Cho
Pil Soo Sung
Han Ah Lee
Ji Hoon Kim
Si Hyun Bae
Jin Mo Yang
Kyung-Suk Suh
Mamun Al Mahtab
Soek Siam Tan
Zaigham Abbas
Ananta Shresta
Shahinul Alam
Anil Arora
Ashish Kumar
Pravin Rathi
Ruveena Bhavani
Charles Panackel
Kuei Chuan Lee
Jun Li
Ming-Lung Yu
Jacob George
Tawesak Tanwandee
Sen-Yung Hsieh
Chee Chien Yong
Mohamed Rela
H. C. Lin
Masao Omata
Shiv Kumar Sarin
for Asian Pacific Association for Study of Liver (APASL)
Publication date
28-02-2024
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10629-3

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue

Original Article

Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity

Original Article

Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma

Original Article

The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors

Letter to the Editor

Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis

Original Article

New prognostic model for hospitalized patients with alcoholic cirrhosis and Maddrey’s discriminant function <32

Original Article

Dairy products intake and prevalence, incidence, and recovery of non-alcoholic fatty liver disease in Chinese population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits